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ABSTRACT 
 
Advances in exome sequencing and the development of exome genotyping arrays are 
enabling explorations of association between rare coding variants and complex traits 
using sequencing-based GWAS. However, the cost of sequencing remains high, optimal 
study design for sequencing-based association studies is an open question, powerful 
association methods and software to detect trait-associated rare and low-frequency 
variants are in great need. Containing 5% of information in human genome sequence, 
chromosome X analysis has been largely neglected in routine GWAS analysis. In this 
dissertation, I focus on three topics: 
 
First, I describe a computationally efficient approach to re-construct gene-level 
association test statistics from single-variant summary statistics and their covariance 
matrices for single studies and meta-analyses. By simulation and real data examples, I 
evaluate our methods under the null, investigate scenarios when family samples have 
larger power than population samples, compare power of different types of gene-level 
tests under various trait-generating models, and demonstrate the usage of our methods 
and the C++ software, RAREMETAL, by meta-analyzing SardiNIA and HUNT data on 
lipids levels.  
 
Second, I describe a variance component approach and a series of gene-level tests for X-
linked rare variants analysis. By simulations, I demonstrate that our methods are well 
   
 x  
controlled under the null. I evaluate power to detect an autosomal or X-linked gene of 
same effect size, and investigate the effect of sex ratio in a sample to power of detecting 
an X-linked gene.  Finally I demonstrate usage of our method and the C++ software by 
analyzing various quantitative traits measured in the SardiNIA study and report detected 
X-linked variants and genes. 
 
Third, I describe a novel likelihood-based approach and the C++ software, RAREFY, to 
prioritize samples that are more likely to be carriers of trait-associated variants in a 
sample, with limited budget. I first describe the statistical method for small pedigrees and 
then describe an MCMC approach to make our method computationally feasible for large 
pedigrees. By simulations and real data analysis, I compare our approach with other 
methods in both trait-associated allele discovery power and association power, and 
demonstrate the usage of our method on pedigrees from the SardiNIA study.  
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CHAPTER 1: INTRODUCTION 
Mapping Human Complex Traits 
Focus of gene mapping of human complex traits migrated from linkage studies to 
association studies gradually since the end of the 20
th
 century. As pointed out by [Risch 
and Merikangas 1996], association studies can have greater power than linkage studies 
but were limited by the fact that not many polymorphisms or genes were identified at that 
time. The number of markers that were available for analysis was usually in the tens and 
sample size was in the hundreds. 
 
Advances in genotyping technology and rapidly reduced genotyping cost in the beginning 
of the 21
st
 century have facilitated detecting a large amount of polymorphisms across the 
entire human genome and brought a plethora of discoveries through genome-wide 
association studies (GWAS) for various human complex diseases and traits [Teslovich et 
al. 2010; Willer et al. 2008]. Genotyping arrays allow scientists to analyze association of 
variants that are in linkage disequilibrium with causal variants, instead of analyzing 
markers that might be several cM away from the causal gene on the same chromosome in 
linkage studies. However, , because not enough features could be captured on the chip, 
polymorphisms studied in GWAS were usually relatively common in frequency, which 
has been shown to contribute to a very small proportion of human DNA variations 
according to the observations from 1000 Genome Project [Abecasis et al. 2010]. The fact 
that GWAS findings altogether were not able to fully explain the trait variance  brought 
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up the well-known “missing heritability” question. A natural conjecture for a possible 
solution of this question was that rare and low-frequency variants with large effects might 
exist and could explain the missing heritability, but we were simply not able to detect 
them.  
Advances in Sequencing Studies 
While  array-basedGWAS continued to succeed, sequencing technology has been 
improving at a fast speed and sequencing cost has been decreasing rapidly. In 2014, a 
decade after the completion of the first GWAS, whole-genome sequencing cost reached 
the $1,000 per genome milestone. Unlike in array-based GWAS, sequencing makes it 
possible to analyze causal genes and variants directly instead of studying their linkage 
disequilibrium proxies - the common variants that are in linkage disequilibrium with 
them. Many sequencing studies have been conducted or are on-going [Lange et al. 2014; 
T2D-GENES-Consortium,In Preparation].  
 
Sequencing also allows discoveries of rare and low-frequency variants with moderate to 
large effects which are expected to explain at least part of the “missing heritability” 
mystery. Although, at present, there is no sequencing study that is able to show that rare 
variant discoveries could explain the missing heritability from GWAS findings fully for 
any trait, thorough investigations of rare and low-frequency variants are expected to bring 
biological insights to biology of human diseases and traits because rare variants are more 
likely to be functional [Nelson et al. 2012]. Besides whole-genome sequencing, exome 
sequencing and exome chip arrays are also cost-effective strategies for rare and low-
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frequency discoveries and significant amount of successful findings have been reported 
[Crosby et al. 2014; Lange et al. 2014].  
 
Sequencing studies can also provide valuable source to generate imputation reference 
panels to increase imputation accuracy for rare and common variants. Imputation using 
reference panels generated from 1000 Genome sequencing study has become routine 
analysis in GWAS. Sequencing a proportion of samples from a cohort to build an 
enriched reference panel with disease-causing rare mutations together with the currently 
existing reference panel followed by imputation to large well-phenotyped cohort can 
greatly enlarge power to detect trait-associated or disease-causal genes [Hoffmann et al. 
2015]. The Haplotype Reference Consortium (HRC) [REF] creates a large reference 
panel of human haplotypes combining whole-genome sequencing data from multiple 
cohorts, enabling imputation of large amount of rare and low-frequency variants to 
enlarge GWAS power.   
Challenges in Sequencing-based GWAS 
Challenges are non-negligible for design and analysis of sequencing-based genome-wide 
association studies.  First, optimal study design for sequencing-based GWAS is an open 
question. Family samples were essential for linkage studies because transmission patterns 
which are the core to detect linkage signal, can  be tracked or inferred in pedigrees. 
Array-based GWAS largely used population samples, because unrelated samples 
naturally have large power to detect common variants in association than family samples. 
However, in sequencing-based GWAS, rare and low-frequency variants are the focus for 
association analysis, and sampling unrelated individuals from a population requires very 
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large sample size to be able to capture enough rare alleles for enough power. Family 
samples sometimes can capture more than average copies of rare alleles due to the 
“Jackpot” effect where multiple copies of a rare allele can be observed in a single 
pedigree. But how this could affect association power remains an open question. What’s 
more, sequencing cost remains high. Novel methods for cost-efficient study design of 
sequencing studies are in great need.  
 
Second, detecting the associations of rare and low-frequency variants that contribute to 
the majority of polymorphisms from sequencing data has extremely limited power unless 
there are large enough samples to be sequenced or large enough number of rare alleles 
captured. One popular strategy is to aggregate rare variants within a gene or a region to 
bring a synergy of information to enlarge power. Many different statistical methods have 
been published and they can be summarized into two types of gene-level association 
methods based on whether genetic effect of a gene is modeled as a fixed effect, for 
example, in burden [Li and Leal 2008; Madsen and Browning 2009] and Variable 
Threshold [Lin and Tang 2011; Price et al. 2010] tests, or random, for example, Sequence 
Kernel Association Test (SKAT) [Wu et al. 2011] and SKAT-O [Lee et al. 2012a]. These 
gene-level tests have certain advantages and disadvantages for different disease models. 
For example, burden type tests are more powerful when causal variant counts in a gene is 
large and all causal variants have effect sizes of the same direction, yet loses power 
quickly when causal variants are bi-directional; kernel-based variance component tests, 
such as SKAT, are most powerful when causal variant count is small or causal variants 
have opposite directions in effect sizes. The other popular strategy is Meta-analysis, 
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which has been extremely successful in array-based GWAS studying common variants 
[Scott et al. 2007; Willer et al. 2010]. Meta-analysis naturally enlarges power by 
increasing sample sizes without sharing raw data. However, powerful meta-analysis 
association methods for sequencing data for family samples are sparse. Many association 
methods for quantitative traits to detect single common variant associations in nuclear 
families and sib-pairs [Abecasis et al. 2000; Abecasis et al. 2001b; Laird et al. 2000], and 
in general pedigrees [Chen and Abecasis 2007] have been published. But gene-level tests 
and meta-analysis methods for rare variant associations in families are under 
development. 
 
Third, chromosome X association analyses have been largely neglected in array-based 
GWAS, although containing 5% of human DNA sequences. X-linked QTL linkage 
analysis methods have been extensively studies and implemented in tools that are widely 
used [Abecasis 2002; Abecasis et al. 2000; Almasy and Blangero 1998; Lange and Sobel 
2006]. X-linked single variant association tests for quantitative traits in unrelated and 
related samples have also been studied [Abecasis 2002; Clayton 2008; Clayton 2009; 
Zhang et al. 2009]. However, gene-level association methods and meta-analysis methods 
for X-linked rare and low-frequency variants are in great need.  
Outline of this Thesis 
In this dissertation, I focus on three topics related to design and association methods for 
sequencing data analysis for quantitative traits. First, I describe the gene-level association 
and meta-analysis methods for sequencing data in family and population samples [Feng 
et al. 2015]. Second, I address the association methods for X-linked rare and low-
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frequency variants in family and population samples. Third, I describe a novel likelihood-
based method to prioritize samples that are more likely to carry trait-associated rare 
variants. 
 
In chapter 2, I investigate the advantages and disadvantages of family and population 
samples in modern genetic association studies, especially sequencing-based GWAS. I 
describe scenarios when family samples have more power than population sample using 
simulation. I then propose efficient gene-level association methods for single studies and 
for meta-analysis of family and population samples. By simulations, I seek to 1) 
demonstrate that our methods are well calibrated under the null by calculating type I 
errors and 2) compare power of different gene-level association tests under various trait-
generating model and 3) compare power and computational performance of our method 
and software with other published methods and tool. Finally, using SardiNIA and HUNT 
exome chip data, I demonstrate the usage of our methods in meta-analysis by finding 
confirmed trait-associated genes for blood lipid traits. 
 
In chapter 3, I describe our statistical approach to analyze X-linked rare variants. I 
describe a variance component model to properly handle relatedness and cryptic 
relatedness and population structure in a sample. By simulations, I demonstrate that 1) 
our methods are under control under the null and 2) there is larger power to detect a X-
linked gene than an autosomal gene with the same effect when complete X-inactivation is 
assumed and then I further evaluate the relationship between power and proportion of 
females in a sample. Finally, using SardiNIA quantitative traits and exome chip data, I 
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demonstrate the usage of our method and tool and report associated X-linked genes and 
rare variants to some of the quantitative traits measured in SardiNIA sample.  
 
In chapter 4, I describe a novel likelihood-based approach to select samples that are more 
likely to carry trait associated rare variants in a currently existing sample, with limited 
sequencing cost. I first describe the statistical method for small pedigrees and then 
describe an MCMC approach for large pedigrees to make our method computationally 
feasible. By simulations, I compare our approach with methods that select phenotypic 
extremes by evaluating both trait-associated allele discovery power and association 
power, and I demonstrate that our method is not affected by the choice of prior values of 
frequency and effect size. Finally, using SardiNIA data, I demonstrate the usage of our 
method on large pedigrees (as many as ~1,200 individuals per family) and show that our 
method has larger discovery power than the competing method which considers only 
phenotypic extremes.  
 
In chapter 5, I summarize my work and propose possible interesting topics in design and 
analysis methods for sequencing-based studies. 
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CHAPTER 2: STUDY DESIGN AND ASSOCIATION AND META-ANALYSIS 
METHODS IN FAMILIES 
Introduction 
Variants of functional consequence, including non-synonymous, splice altering, and 
protein truncating variants, usually segregate at very low frequency in human 
populations [Abecasis et al. 2010; Abecasis et al. 2012; Marth et al. 2011; Nelson et 
al. 2012]. Recent advances in exome sequencing and the development of exome 
genotyping arrays are enabling explorations of their contributions to complex 
disease [Kiezun et al. 2012]. 
 
Association of rare variants with disease will bring biological insights about disease 
processes, but standard variant-by-variant association tests lack power when 
applied to these variants unless sample sizes are very large. Our work builds upon 
three strategies to increase the power of rare variant association studies: grouping 
variants by gene or functional unit, combining results across many studies through 
meta-analysis, and analysis of family samples. 
 
Grouping rare variants by gene or functional unit [Li and Leal 2008], whether with 
weights [Madsen and Browning 2009] or without [Morris and Zeggini 2010], is now 
a popular strategy for rare variant association analysis [Lee et al. 2012a; Lee et al. 
2012b; Lin and Tang 2011; Price et al. 2010; Wu et al. 2011]. The approach assumes 
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that rare variants in the same gene or functional unit have similar functional 
consequences. When the assumption is correct and rare variants in a region are 
analyzed together, association signals will be  stronger than when evaluating 
variants individually. 
 
A second strategy to increase power is meta-analysis, which increases sample size 
and provides a practical approach to difficulties in data-sharing and concerns about 
heterogeneity [Lin and Zeng 2010; Willer et al. 2010].  Meta-analysis of single 
variants has been key in establishing association between common variants and 
complex diseases [Scott et al. 2007; Willer et al. 2010]. Meta-analysis methods for 
rare variant association tests have now been proposed, although these initial 
proposals and their implementations have generally focused on samples of 
unrelated individuals [Lee et al. 2013; Liu et al. 2014; Tang and Lin 2013]. 
 
Finally, a third strategy is to study samples of closely related individuals, increasing 
the odds that multiple copies of each rare variant are observed. Family samples are 
key in studies of Mendelian disorders but can also have advantages for studies of 
complex traits [Laird and Lange 2006, 2008; Ott et al. 2011]. For example, they can 
be more robust to population stratification (which may be more acute in rare 
variant association studies [Gravel et al. 2011]), allow checks for genotyping errors, 
improving data quality [Abecasis et al. 2001a; Abecasis et al. 2002][Abecasis et al. 
2001; Abecasis et al. 2002] and can be enriched for variants of large effect by 
focusing on families with multiple individuals with extreme phenotypes. Early tests 
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for family based association [Abecasis et al. 2000; Laird et al. 2000; Laird and Lange 
2008] focused on analysis of transmission disequilibrium, but newer tests rely on 
variance component models [Chen and Abecasis 2007; Kang et al. 2010] to account 
for stratification, resulting in tests of association that are typically more powerful 
[Chen and Abecasis 2007]. Our work also builds on computational enhancements in 
methods for variance component analysis, which have now been extended to 
samples of unrelated individuals (using empirical kinship matrices, estimated from 
genotype data) [Kang et al. 2010; Lippert et al. 2011; Zhou and Stephens 2012]. 
 
Here, we describe family-based association tests for rare variants that allow analysis 
of quantitative traits, with or without covariates, and show how these tests can be 
applied in meta-analysis settings. Our methods are based on the insight that gene-
level test statistics can be constructed from single variant score statistics and 
estimates of the covariance between those [Liu et al. 2014]. We first analyze single 
variants using efficient computational algorithms for evaluation of variance 
component models [Lippert et al. 2011]. We then develop family-based burden 
(weighted and un-weighted), sequence-kernel association (SKAT), and variable 
frequency threshold (VT) tests. Using simulation we show that type I error is well 
controlled and compare different testing approaches. As expected, SKAT tests are 
more powerful when the fraction of associated variants in each gene is small or 
associated rare variants have opposite directions of effect; VT tests are more robust 
to the choice of allele frequency threshold for grouping variants. Our analysis of 
exome chip genotypes and HDL level data from the HUNT and SardiNIA studies 
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shows that our methods are well calibrated and powerful enough to identify several 
signals at lipid associated loci. 
 
There has been much recent work focused on extending gene-level association tests 
to families. Examples include various family-based burden tests [De et al. 2013; Saad 
and Wijsman 2014; Schaid et al. 2013] and variance component based tests [Chen et 
al. 2013; Ionita-Laza et al. 2013; Saad and Wijsman 2014; Schaid et al. 2013; 
Schifano et al. 2012; Svishcheva et al. 2014]. A key difference in our implementation, 
compared to previous work is that we construct our gene-level statistics using 
single-variant statistics as input. This allows us to quickly re-evaluate gene-level 
statistics when gene definitions or variant masks change, makes it practical to 
implement variable frequency-threshold based tests, and facilitates meta-analyses. 
To ensure computational efficiency in genome-wide analyses, our implementation 
uses a score-test that requires fitting a maximum likelihood model only once, rather 
than a Wald-test that would require it for every gene [Saad and Wijsman 
2014]Madsen and Browning 2009]. We also focused on methods that could 
accommodate a diverse mix of family structures or even samples that include both 
families and unrelated individuals. This is in contrast to transmission-based tests 
[De et al. 2013; Ionita-Laza et al. 2013] that are limited to simpler family structures 
and cannot account for cryptic relatedness. As usual, we expect transmission based 
tests may provide greater protection against stratification – but at the cost of greatly 
reduced power.   
 
   
 12  
We characterize settings where family studies can provide greater power to detect 
rare variants with moderate to large phenotypic consequences than studies of 
unrelated individuals. In studies of unselected samples, this is due to a “Jackpot” 
effect, where multiple copies of a extremely rare allele can be observed in a single 
pedigree. While for each locus the expected number of rare alleles will be the same 
in a family sample or an unrelated sample of same size, family samples are much 
more likely to exceed this expectation by a large amount. Our simulations show that 
this difference can have a large impact on power. All the methods described here are 
implemented in freely available C++ code and tools. 
Methods 
 
In this section, we first describe a variance component model to handle familial 
relationships. Then, we describe how single variant association statistics and their 
covariance matrices can be calculated and how gene-level association tests can be 
constructed. Next, we describe meta-analytic approaches for both single variant and 
gene-level association tests. Finally, we discuss the computational cost of our 
proposed approach and provide practical suggestions to improve computational 
performance.  
Modeling Relatedness 
 
In a sample of n individuals, we model the observed phenotype vector (y) as a sum 
of covariate effects (specified by a design matrix X and a vector of covariate 
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effects 𝜷 ), additive genetic effects (modeled in vector g) and non-shared 
environmental effects (modeled in vector 𝝐). Thus: 
𝐲 = 𝐗𝛃 + 𝐠 + 𝛜.    (Equation 1) 
We assume that genetic effects are normally distributed, with mean 0 and 
covariance 2σg
2𝐊  where the matrix K summarizes kinship coefficients [Lange 1997] 
between sampled individuals and  𝜎𝑔
2 is a positive scalar describing the genetic 
contribution to the overall variance. We assume that non-shared environmental 
effects are normally distributed with mean  and covariance 𝐈σe
2, where I is the 
identity matrix. 
 
To estimate K, we either use recorded pedigree structure to define ?̂? following the 
method described in [Lange 1997] or else use the Balding-Nicols empirical 
estimator [Astle and Balding 2009], which uses observed genotypes to estimate 
kinship as  ?̂? =
1
𝑣
∑
(𝐆𝐢−2𝑓𝑖𝟏)(𝐆𝐢−2𝑓𝑖𝟏)
𝐓
4𝑓𝑖(1−𝑓𝑖)
𝑣
𝑖=1 (here, v is the count of variants, 𝐆𝐢 is a 
genotype vector where each element encodes the number of observed minor alleles 
in a particular individual, and fi is the estimated allele frequency for the ith variant). 
Model parameters ,  and , are estimated using maximum likelihood and the 
efficient algorithm described in Lippert et al. [Lippert et al. 2011]. For convenience, 
let the estimated covariance matrix of  be ?̂? = 2σg2̂?̂? + 𝜎𝑒2̂I.  
Single-variant Association Tests and Summary Statistics 
 
0
y
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Since our gene level association tests will build on single-variant test statistics [Chen 
and Abecasis 2007], we will first describe single variant test statistics and their 
corresponding variance-covariance matrix.  
Consider the model 
. 
This model is a refinement of equation (1) above, adding a scalar parameter  to 
measure the additive genetic effect of the ith variant. As usual [Lange 1997], the 
score statistic for testing  is 
  
And the variance-covariance matrix of these statistics is: 
                        . 
Under the null, test statistics  are asymptotically distributed as chi-squared 
with one degree of freedom. 
Gene-level Association Tests for Family Samples 
 
Using single variant statistics and their variance-covariance matrix V, we are 
now ready to construct a variety of gene-level association test statistics that 
combine information across variants.  
 
The simplest statistic for a burden test is to estimate the average genetic effect 
across a series of variants satisfying certain functional (for example, non-
U i
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synonymous or protein truncating variants) and frequency criteria (for example, 
allele frequency <.05).  Then the rare variant burden for each individual can be 
defined as a weighted sum of allele counts for variants satisfying these criteria. 
Abstractly, we define the rare variant burden as , where 
 is a vector of weights for each of the  variants in the gene. A 
regression parameter measuring the average effect of each variant can be estimated 
using the model: 
. 
To test the null hypothesis , we use a score statistic, expressed as a function of 
single variant statistics  with variance . 
Then the burden test statistic  is asymptotically normal with mean 
zero and variance one.  
Variable Threshold Tests for Family Samples 
 
The simplest burden tests will be effective when appropriate frequency thresholds 
and functional annotation are used to select functional variants for analysis. 
However, this is challenging to do, because the optimal frequency thresholds will 
vary by gene and by phenotype [Lange et al. 2014]. One possibility is to define a test 
statistic that considers many alternative frequency thresholds [Lin and Tang 2011; 
Price et al. 2010]. 
 
m
wTU wTVw
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Following the suggestions of Price et al. 2010 and Lin et al. 2011, we will define the 
variable threshold test statistic as the maximal absolute value of burden test 
statistics across all possible frequency thresholds, , where 
 is the burden test statistic calculated with frequency threshold F 
and  is a vector of 0s and 1s indicating whether a variant has allele frequency 
below F. Burden statistics calculated using different frequency thresholds jointly 
follow a multivariate normal distribution with mean 0, and variance-covariance 
matrix  [Lin and Tang 2011]P-values can be evaluated using the 
cumulative density function of this multivariate normal distribution [Genz 1992]. 
Sequence Kernel Association Tests 
 
Another refinement is to use a test statistic that allows for variants in the same gene 
to modify the phenotype in opposite directions [Chen et al. 2013; Ionita-Laza et al. 
2013; Wu et al. 2011; Yan et al. 2014]. For example, in some genes [Abifadel et al. 
2003], both gain-of-function and loss-of-function alleles have been described and 
these signals might cancel each other in a standard burden analysis. The model for 
this type of test is 
, 
In this alternative model, the single variant effects are assumed to follow a shared 
distribution, with mean 0 and variance twi. We test the null hypothesis of no 
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association using the statistic  to evaluate whether  is nonzero 
[Chen et al. 2013; Wu et al. 2011]. As usual,   is a diagonal 
matrix indicating the weight of each variant. TSKAT is distributed as a mixture chi-
squared with weights  corresponding to the eigenvalues of , and 
the χ1
2(𝑖) correspond to independently distributed chi-squared variables, each with 
1 degree of freedom [Wu et al. 2011]. P-values can be approximated using the 
Davies algorithm [Davies 1980] or a moment matching algorithm [Liu et al. 2009]. 
Meta-Analysis 
 
Since we derived all the statistics above from single variant score statistics and their 
covariance matrix, our approach can be readily extended to meta-analyses. We first 
define the overall single variant score statistics and their variance-covariance 
matrix as  and , where  and  are the single 
variant score statistic and variance-covariance matrix components from study  
and  is the total number of studies. Whenever variant i is unobserved in study k, 
we set Uik = 0 and Vij,k = 0 for all j.  Next, we simply calculate burden, VT and SKAT 
meta-analysis statistics using the formulae above. 
Computational Efficiency 
 
Since we rely on score statistics and their covariance, we only need to fit the linear 
mixed model once under the null hypothesis. Fitting parameters for this null mixed 
model is a major part of the computational cost of our approach. Standard EM or 
wm )
V
1
2WV
1
2
U ik Vij,k
k
s
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Newton–Raphson methods require calculating the inverse of the covariance matrix 
in each iteration – with time complexity O(n3), too costly for large datasets. Instead, 
we used the computationally efficient algorithm described in  [Lippert et al. 2011] to 
estimate the variance components and fixed effects under the null (Equation 1). 
The algorithm begins with a one-time singular value decomposition (SVD) of the 
relationship matrix , a step which has time complexity O(n3). The results of this 
decomposition are used in a factorization that transforms the phenotype vector and 
design matrix so that transformed phenotypes are identically and independently 
distributed. This second step has time complexity O(n2). After transformation, the 
cost of updating the log likelihood becomes linear with respect to sample size n 
(instead of O(n3) using the standard approach). Calculating the score statistics and 
their covariance for all single variants simply requires a transformation of 
genotypes and has time complexity O(mn2) for a dataset with m variants. In reality, 
we calculate covariance of score statistics from markers within a sliding window. 
For large samples, calculating the SVD of  is the computationally most expensive 
step. A similar idea with comparable computational efficiency has also been 
described in Zhou and Stephens (2012]. Both ideas build upon the algorithm 
described by Kang et al. and implemented in EMMAX [Kang et al. 2010]. 
 
When variants are grouped in gene-level tests, the computational cost of calculating 
the combined test statistics is small after single variants have been analyzed. 
Obtaining p-values corresponding to these statistics, especially for SKAT and VT 
analyses, can still be challenging when the number of rare variants in a gene is large. 
Kˆ
Kˆ
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To speed up this step, we used computationally efficient algorithms to evaluate the 
multivariate normal probabilities [Genz 1992] and the mixture chi-squared 
distribution [Davies 1980]. 
Simulation 
 
We carried out a series of simulations to evaluate the type I error and power of our 
method. We first simulated a set of 1000 base-pair sequences, which is close to the 
length of an average protein coding sequence in humans, using the coalescent (as 
implemented in the program ms [Hudson 2002]) and a demographic model  
calibrated to mimic European population history [Adams and Hudson 2004; 
Novembre et al. 2008]. We then carried out gene-dropping simulations [Abecasis et 
al. 2002] using these simulated sequences as founder haplotypes that were 
propagated through various pedigree structures (Figure 2.1).  
 
To evaluate power, we assigned a fraction of variants below a desired frequency 
threshold (<0.01 in simulations unless addressed otherwise) as causal. Typically, we 
assigned minor alleles at causal variants to all have effects in the same direction but, 
in some cases, a fraction of causal minor alleles were assigned effects in the opposite 
direction. When assigning effect sizes to causal variants, we considered two trait-
generating models - an equal variance model (where the effect size for each variant 
is proportional to , a function of the allele frequency p that ensures each 
causal variant explains the same amount of trait variance) and an equal effect-size 
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model (where the effect size is the same for all causal variants, irrespective of allele 
frequency). In the equal effect size model, relatively common variants explain a 
larger amount of the variance; while in the equal variance model, rarer variants 
have larger effect sizes (See Figure S2.1 for demonstration). Genetic effects were 
set so that the total variance explained by each gene (h2gene) was in the 0.1-2% 
range. Empirical power was calculated using 10,000 simulations for each parameter 
combination. We used =1x10-8 for single variant association power and =2.5x10-
6 for gene-level association power, following the consensus of significance level used 
in GWAS with Bonferroni correction. Type I error rate for gene-level tests was 
estimated using 5,000,000 simulations. To compare studies of families and 
unrelated individuals, we held the number of genotyped (or sequenced) individuals 
constant and compared our power to detect associated variants in studies using 
different sampling units. In simulations and following association analysis, kinship 
matrices estimated from pedigree were used to fit the null linear mixed model. 
SardiNIA and HUNT Samples Description 
 
To demonstrate usage of our methods in real data analysis, we used exome chip data 
from the HUNT [Holmen et al. 2014a; Holmen et al. 2014b] and SardiNIA [Giorgio et 
al. 2014; Pilia et al. 2006] studies, which genotyped 5,803 and 6,602 individuals, 
respectively. Here, we analyze HDL, adjusted for age and sex (Table S2.3). 
Genotypes were called using the Illumina GenCall algorithm in combination with 
zCall V2.2. Detailed QC procedures can be found in Holmen et al. [Holmen et al. 
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2014a] for the HUNT study and Pistis et al. [Giorgio et al. 2014] for the SardiNIA 
study.  
Results 
Type I Error Rate 
To evaluate type I error rate, we simulated family samples of 1,000 or 5,000 
individuals with with families of 3 generation pedigrees with 10 (Pedigree10) or 50 
(Pedigree50) individuals (see Figure 2.1 for details). Within each gene, variants 
with frequency <.01 were grouped for analysis. Each type I error estimate 
summarizes results from five-million simulations. Table S2.1 shows that the type I 
error of our gene-level association tests is well controlled for a variety of pedigree 
structures. Empirical error rates are a little below nominal levels when sample sizes 
are small (N=1,000), but approach nominal significance as sample size increases 
(N=5,000).   
Power of Different Rare Variant Association Tests 
Next, we evaluated the power of our proposed association tests under various 
scenarios. We used significance level =2.5x10-6, which corresponds to Bonferroni 
adjustment for testing of 20,000 genes. We first simulated samples of 5,000 
individuals distributed in 3-generation pedigrees with 10 individuals each 
(Pedigree10 in Figure 2.1). Variants with frequency <1% (<5% where noted) 
explained 1% of the variance in a simulated quantitative trait. When all associated 
variants had the same effect size and the proportion of causal variants was small 
(~20%), SKAT had the largest power. When this proportion grew larger (~80%, 
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although this might not be very realistic, we increased the proportion to 80% for 
scientific investigation), VT became the most powerful test (Table 2.1). Although 
we did not simulate a relationship between frequency and effect size among causal 
variants, VT provided greater power because it sometimes excluded relatively 
common unassociated variants from consideration, reducing noise. When fraction of 
causal variants is small, methods that explicitly allow for heterogeneity in effect 
sizes do better, since no correlation between causality and effect size was simulated, 
VT can’t easily exclude most of the unassociated variants. In practice, the true list of 
causal variants is usually unknown; and allele frequency is often a good proxy to 
identify variants likely to modify gene function [Nelson et al. 2012].  In a simplified 
scenario where only causal variants were grouped and other variants were 
discarded, the basic burden test became optimal (Table 2.1).  
 
We next considered more complex scenarios. When 20% causal variants decreased 
trait values and the remainder increased trait values, the power of burden and VT 
tests dropped dramatically and SKAT became the most powerful test, regardless of 
the proportion of causal variants (Table 2.2). When we set up our simulation so 
that each variant explained the same fraction of trait variance (and, thus, so that 
rarer variants had larger effects), SKAT remained the most powerful test when the 
proportion of causal variants was small, but the Madson-Browning weighted burden 
(MB) test outperformed VT and SKAT when the proportion of causal variants was 
large (80%) (Table 2.3). This was expected since, in this setting, relative effect sizes 
match those predicted by the Madson-Browning weighting scheme.  
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Power when Misspecifying Frequency Threshold 
 
We next investigated the impact of misspecifying frequency thresholds during 
analysis. Figure S2.2A shows that when causal variants have the same effect sizes, 
VT and Madson-Browning-weighted burden tests perform well as long as the 
frequency cut-off used during analysis is larger than the cutoff used for simulation. 
In contrast, the power of SKAT and simple burden tests is greatly reduced when 
incorrect frequency thresholds are used for analysis. Figure S2.2B shows that when 
rare causal variants have larger effects and all variants explain the same amount of 
trait variance, all tests reach maximum power at a frequency threshold less than or 
equal to 0.01, the threshold for simulating causal variants. Whereas the power of VT 
and MB remain close to optimal, the power of SKAT and the simple burden tests 
drops greatly as the frequency threshold used for analysis increases and non-causal 
and small effect variants enter the analysis. In real data analysis, because true 
disease model is unclear, we recommend multiple frequency thresholds should be 
used when using SKAT or simple burden tests [Lange et al. 2014]. 
Relative Power of Family Samples and Unrelated Individuals 
 
We used simulations to compare the benefits of samples of families and unrelated 
individuals in association studies. Family samples can allow many copies of the 
same trait associated rare alleles to be observed in a single study. Variability in 
allele counts is larger in families, particularly in pedigrees with many descendants 
for each founder. For example, for a variant with allele frequency 0.0005 (~5 alleles 
expected when 5000 individuals are sequenced), the standard deviation of the allele 
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counts in a sample matching Pedigree50 (from Figure 2.1) is >3 times larger than a 
sample of unrelated individuals (see Table S2.2 for details) – meaning that the 
chance of observing >10 copies of the variant is 20% when families matching 
Pedigree50 are sampled, but 4% in samples of unrelated individuals.  
 
We speculated that the increased variability in allele counts in family samples would 
mean that family samples might sometimes hit a “jackpot” and sample many copies 
of a trait associated rare allele, increasing power. This speculation was supported by 
our simulations: a sample of 5,000 individuals in families matching Pedigree50 
provides >2-fold greater power to detect a variant with frequency 0.001 and effect 
size 1 than a population sample of the same size (power was 0.9% in sample of 
unrelated individuals and 2.3% in sample of families, Figure S2.3). This increase 
may seem paltry, but it is important to remember that many susceptibility loci 
underlie each human complex trait: if there are hundreds of such loci and power 
increases from 0.9% to 2.3% at each of those, the odds of a successful discovery will 
increase dramatically. The idea of “jackpot” effect was also supported by close 
examination of our simulation results. Among all 10,000 simulated samples, the 
average frequency of trait associated alleles was 0.0010, but in samples that have 
association p-value <1x10-8, the frequency of trait associated alleles was higher, 
averaging 0.0032, a >3 fold increase. The relative advantages of family samples over 
unrelated samples decrease in settings where power (and, typically, the number of 
expected rare allele carriers) is high. For example, when sample size increases, allele 
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frequency increases, or effect size (or variance explained) increases unrelated 
samples quickly become more powerful (Figure S2.3). 
 
Consistent with patterns in single variant association power, Figure 2.2 shows that 
family studies have the similar advantages in studies of gene-level rare variant 
associations. For example, in a sample of 5,000 individuals, power to detect a gene 
where 20% of variants with frequency <1% are causal and explain 0.5% trait 
variance increases from 1% for unrelated individuals to 13% for family samples. 
 
Advantages in power from studies of families are strongly correlated to the variance 
of allele counts (which is a function of family size and pedigree structure). For 
example, a sample of families matching Pedigree50 (Figure 2.1) has largest 
variance in allele counts (Table S2.2) and also the largest power for detecting a 
gene explaining 0.5% of trait variance in a sample of 5,000 individuals (Figure 2.3), 
whereas a sample of families matching Nuclear4 (Figure 2.1) has the smallest 
variance in allele counts and provides the smallest increase in power relative to 
samples of unrelated individuals (in this simulation, 20% of variants with frequency 
1% were causal). All family samples have larger variance in allele counts than 
unrelated samples. For example, for a variant with frequency .1%, the standard 
deviation of the allele count in family samples with 5,000 individuals in Pedigree50 
structure is 10.3, which is ~3 times the standard deviation of allele counts from 
unrelated samples of the same size.  
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The advantage of family samples extends to extremely rare variants. Figure 2.4A 
shows that when 20% of singleton variants (defined as alleles present only once in 
our initial pool of 10,000 simulated sequences) in a gene were causal explaining 
0.5% trait variance, power to detect gene-level association increased dramatically 
from 3.5% in a study of 5,000 unrelated individuals to as much as 19.3% in a study 
of 5,000 related individuals. Figure 2.4B shows that when sample size increase to 
10,000 individuals, the window where family samples are more advantageous 
becomes narrower.  
 
In all examples highlighted so far, family studies outperform studies of unrelated 
individuals but in all of these examples power was low for both families and 
unrelated individuals. We expect that this is actually a common situation in human 
genetic studies – there may be very large numbers of trait associated loci but any 
single study may only provide enough power to detect a few of these. To explore 
this situation directly, we estimated power to detect at least one of several disease-
associated loci. Assuming power to detecting association at a specific gene is p and x 
genes with similar effect variants exist, then the power to detecting at least one of 
these is 1-(1-p)x, assuming independent genes. Figure 2.5 shows dramatic 
advantages in the power to detecting at least one of 20 trait associated genes, each 
explaining the same proportion of trait variance. For example, power to detect at 
least one gene explaining 0.5% trait variance (when 20% variants in the gene and 
with frequency <1% are causal) when 20 such genes exist is >90% in sample of 
5,000 individuals distributed in families matching Pedigree50 (Figure 2.1), whereas 
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only ~20% in a sample of 5,000 unrelated individuals. The power advantage in 
family samples increases with the variability in allele counts, which in turn is driven 
by pedigree structure (Figure 2.6).  
 
Families matching Pedigree50 are not easy to find. For a more realistic comparison 
of the power of studies of families and unrelated individuals, we repeated our 
simulations using the family structures and phenotypes observed in the SardiNIA 
sample. To preserve the correlation of phenotypes among family members, we 
started with observed HDL values together with sex, age and age-squared as 
covariates. Figure S2.4 shows that the SardiNIA families provide larger power for 
discovering rare variants with moderate effect sizes than studies of same numbers 
of unrelated individuals. For example, the SardiNIA sample provides 1.6% power to 
detect a variant with frequency 0.0001 and effect of 2.5 trait standard deviation 
units, whereas unrelated samples provide only 0.05% power (Figure S2.4A). If 100 
such variants exist, the SardiNIA sample provides ~80% power to detect at least 
one, but an equal number of unrelated individuals provides only ~5% power to 
detect at least one of such a variant (Figure S2.4B). When allele frequency increases 
(Figure S2.4C, S2.4D, S2.4E, S2.4F), the SardiNIA sample is still advantageous 
when effect sizes are moderate. 
Real Data Analysis Using SardiNIA and HUNT Studies 
 
To evaluate our approach further, we meta-analyzed blood HDL levels for 11,556 
individuals from the HUNT and SardiNIA studies (See Table S2.3 for descriptive 
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statistics for traits). Overall, 93,831 and 76,828 sites were polymorphic in the HUNT 
and SardiNIA studies respectively, resulting in 117,958 polymorphic variants when 
combining the two studies (Table S2.4). Among those, 52,700 variants were shared 
in both studies (Table S2.5), 41,130 variants are unique to the HUNT study, and 
24,128 variants are unique to the SardiNIA study (Table S2.6). Using our meta-
analysis method, both shared and non-shared variants contribute to association 
signals. 
  
We first generated summary statistics for each study adjusting for relatedness using 
empirical kinship matrices estimated from genotype data. Within each sample, test 
statistics were well calibrated with Genomic Control 1.00 in HUNT study and 1.01 in 
SardiNIA sample (See Figure S2.5 for QQ plots). To illustrate the importance of 
taking into account phenotype correlations, consider that analyzing the SardiNIA 
exome chip data and treating the samples as unrelated results in a genomic control 
value of 1.45, which is unacceptably high (results not shown); but using our 
approach, genomic control becomes 1.01. We next proceeded to meta-analyze single 
variants. Figure S2.5 shows that our meta-analysis statistics were also well 
calibrated with genomic control value <1.05, both for common and rare variants. At 
a significance threshold of p<4.23x10-7 (corresponding to 0.05/117,958), we found 
significantly associated low-frequency and rare variants at CETP, LIPC, LIPG, and LPL 
for HDL (MAF < 5%; See Figure S2.6 for Manhattan plots). Significant rare variants 
were only found in LIPC and LIPG (MAF < 1%).  
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We then proceeded to gene-level meta-analyses. Again, test statistics appear well 
calibrated, with genomic control value <1.05 (See Figure S2.7 for QQ plots). Also, by 
examining QQ plots from SardiNIA and HUNT study (See Figure S2.7), we 
discovered that, for family samples or samples from isolated population, in the 
analysis of rare variants, a small number of individuals can be quite influential such 
that all variants that are shared between this set of individuals (or families) will 
exhibit similar and often small p-values. This can lead to apparent inflation in QQ-
plots, where confidence intervals are calculated assuming all statistics are 
independent. At a significance threshold of p<2.84x10-6 (corresponding to 
0.05/17,574 and thus allowing for the number of genes tested), we found 
association at APOC3, CETP, LIPC, LIPG, and LPL for HDL (See Table 2.4 for 
tabulated results and Figure S2.8 for Manhattan plots). Among those, APOC3, LIPG, 
and LPL had evidence of association stronger than the most significant single 
variant in the region. In APOC3, none of the individual low frequency and rare 
variants had p-value lower than 10-4 on its own (Table 2.4).  
Comparison with other Methods and Tools 
 
To validate our approach, we compared our implementation to several others in a 
simulated family sample of 10,000 individuals distributed across 1000 families 
matching Pedigree10 (see Figure 2.1). 4000 genes with 1,000 base-pair were 
simulated in families from a pool of haplotypes. A quantitative trait was simulated 
under the null. Variants with MAF<0.05 were grouped for gene-level tests. Pedigree-
based kinship matrices were used in all analyses. We then analyzed the simulated 
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sample using our own famrvtest (SKAT, burden and VT tests), pedgene (burden and 
Kernel test) [Schaid et al. 2013], famSKAT [Chen et al. 2013], and FFBSKAT 
[Svishcheva et al. 2014]. Figure S2.9 shows that all tests generate well-controlled 
QQ plots under the null. 
 
To compare methods under the alternative, we simulated a dataset of 5,000 
individuals (500 x Pedigree10) with a 1,000 base-pair long gene where 50% 
variants with MAF<0.05 were causal and together explained 1% trait variance. We 
simulated data sets where all causal variants had the same direction and also where 
half of the causal variants had opposite effects. In this simulation, our method 
always matched or slightly outperformed alternative implementations (see Figure 
S2.10). 
 
These comparisons also allowed us to evaluate computation performance and 
requirements for our tool. Wherever possible, we tried to provide faster 
computation, less memory use, while still allowing for flexible input formats and 
varied choices of association tests. famrvtest is a command line tool  implemented in 
C++. It uses computationally efficient algorithms to fit linear mixed models [Lippert 
et al. 2011], and recognizes pedigree-based kinship estimates as block-diagonal 
matrices to save computational effort. For our simulated dataset with 10,000 
individuals and 164,323Z variants distributed across 4,000  genes, analysis with 
famrvtest required 1.5 hours and 1.3GB of memory to calculate both SKAT and 
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burden test statistics, a savings of up to 10-100 fold relative to alternative tools (see 
Table S2.7).  
Discussion 
 
Gene-level association tests and meta-analysis are important tools for discovering 
rare variant associations. We have proposed a series of methods that facilitate these 
analyses in family samples (or in samples where cryptic relatedness is modeled 
using variance components). Our C++ tools implement simple burden tests, 
weighted or un-weighted; and variable threshold tests as well as SKAT tests that 
outperform other tests when only small fractions of variants in each gene are causal 
or when variants with opposite effects reside in the same gene.           
 
We compare the relative benefits of family samples and population samples. By 
simulation, we show that family samples can provide substantially greater power 
for rare variant association studies because of a “jackpot” effect – the potential for 
observing many copies of a trait associated rare variant. This advantage is likely to 
be extremely important in the first generation of rare variant association studies, 
each of which is only expected to detect a small fraction of all the true rare variant 
association signals. An example of successful discovery of such variant is 
rs72658864/V578A in LDLR, a rare variant associated to LDL with effect size 23.7 
mg/dl [Sanna et al. 2011]. This variant was observed with frequency 0.00035 in the 
SardiNIA sample, where it was present in multiple families, but has not yet been 
observed in the 1000 Genomes [Abecasis et al. 2012] or the NHLBI Exome 
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Sequencing Projects [Fu et al. 2013; Tennessen et al. 2012] suggesting that it is rare 
indeed.  
 
We demonstrate the utility of our methods by analyzing two samples with complex 
inter-relatedness. Meta-analysis of SardiNIA and HUNT resulted in a well-calibrated 
genomic control value of 1.02 and increased signal at many loci known to be 
associated with HDL – demonstrating the feasibility of including family samples in 
rare variant meta-analysis. We expect that meta-analysis will be useful not only for 
combining data across studies but also to facilitate analysis of large samples 
genotyped or sequenced across multiple platforms or analyzed using a single 
platform but in a batched manner.  
 
We foresee several potential areas for refinement of our methods. For example, a 
limitation for our current approach to meta-analysis is that cross study relatedness 
and sample overlap are not modeled. In genome-wide studies, it may be possible to 
overcome this limitation by using the genome-wide correlation of test statistics 
between pairs of studies to calculate an adjustment factor that could account for 
overlap or relatedness between individuals in two studies [Lin and Sullivan 2009]– 
as suggested by Lin et al. for single marker meta-analyses. Extension of this idea has 
also been proposed in Han et al. 2013. Extending our methods to non-coding 
variants will also be attractive, particularly since the majority of trait-associated 
variants found to date are located in non-coding regions. A difficulty will be the 
development of good grouping strategies for non-coding variants, where 
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interpretation of functional consequence is more challenging. Another challenge we 
foresee is the extension of our methods to discrete traits. The natural way to do this 
is to consider an underlying continuous liability scale and use multivariate 
integration to fit the model, but there may be more computationally efficient 
alternatives to be discovered. 
 
In summary, we have proposed a series of gene-level association tests for family 
samples and methods for calculating these in a meta-analysis of related and/or 
unrelated samples. We also implemented our methods in freely available and open 
source C++ tools:  http://genome.sph.umich.edu/wiki/FamRvTest and 
http://genome.sph.umich.edu/wiki/RAREMETAL. We hope these tools and methods 
will facilitate the next round of gene-mapping studies.   
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Tables 
Table 2. 1 Power when Causal Variants All Increase Trait Values and Have the Same Effect 
Sizes 
MAF 
Cuto
ff 
Causal 
Percenta
ge 
Group by MAF Cutoff Group Only Causal Variants
b
 
Burde
n 
Madsen
-
Browni
ng 
VT 
SKA
T
a
 
Burde
n 
Madsen
-
Browni
ng 
VT 
SKA
T 
0.01 20% 
9.7 3 
13.
1 
36.6 94.3 86.7 
92.
9 
82.6 
80% 
82.4 64.7 
88.
1 
61 96 82.1 
94.
3 
70.7 
0.05 20% 
14.6 2.6 
24.
9 
36.3 95.4 75.3 
93.
8 
86.5 
80% 
81.3 39.5 
89.
2 
75 96.3 55.3 
94.
3 
82.9 
 
Simulated samples each had 5,000 individuals, organized in families with pedigree10 
structure (See Figure 1). Causal variants were selected among those identified in 
simulated 1,000 base-pair sequences and explained 1% of trait variance. Each causal 
variant had the same effect size and direction. Power is tabulated as a percentage of 
simulations exceeding significance threshold. Significance level α = 2.5 x 10-6 was used 
in all simulations.  
  
a. Power calculated from Madsen-Browning weighted SKAT. 
b. Power when grouping only causal variants. This column represents the largest power 
we can achieve for each simulation setting. 
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Table 2. 2 Power Comparison when Causal Variants Can Have Opposite Effects 
MAF 
Cuto
ff 
Causal 
Percenta
ge 
Group by MAF Cutoff Group Only Causal Variants 
Burde
n 
Madsen
-
Browni
ng 
VT 
SKA
T 
Burde
n 
Madsen
-
Browni
ng 
VT 
SKA
T 
0.01 20% 
4.6 0.4 6.0 36.7 38.9 21.1 
43.
4 
83.2 
80% 
30.5 10.4 
33.
4 
60.0 42.6 18.8 
42.
2 
69.0 
0.05 20% 
11.7 1.3 
15.
0 
35.7 55.4 22.3 
58.
3 
88.3 
80% 
44.0 7.8 
47.
1 
74.7 55.1 12.2 
54.
3 
81.6 
 
Simulated samples each had 5,000 individuals, organized in families with pedigree10 
structure (See Figure 1). Causal variants were selected among those identified in 
simulated 1,000 base-pair sequences and explained 1% of trait variance. Among causal 
variants, 20% were randomly selected to be trait-decreasing, and the rest causal variants 
were trait-increasing. Power is tabulated as a percentage of simulations exceeding 
significance threshold. Significance level α = 2.5 x 10-6 was used in all simulations.  
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Table 2. 3 Power Comparison when Causal Variants All Increase Trait Values and Explain the Same Amount of Trait Variance 
MAF 
Cutoff 
Causal 
Percentage 
Group by MAF Cutoff Group Only Causal Variants 
Burden 
Madsen-
Browning 
VT SKAT Burden 
Madsen-
Browning 
VT SKAT 
0.01 20% 4.3 4.2 9.1 20.8 88.7 94.9 90.8 67.0 
80% 66.9 86.6 85.4 20.1 85.5 97.1 93.8 27.0 
0.05 20% 3.8 5.1 9.3 9.8 78.8 98.0 90.1 53.0 
80% 38.6 88.5 82.1 9.4 56.0 97.9 92.6 12.4 
 
Simulated samples each had 5,000 individuals, organized in families with pedigree10 structure (See Figure 1). Causal variants were 
selected among those identified in simulated 1,000 base-pair sequences and explained 1% of trait variance. Each causal variant 
explained the same amount of trait variance. All causal variants were trait-increasing. Power is tabulated as a percentage of 
simulations exceeding significance threshold. Significance level α = 2.5 x 10-6 was used in all simulations.  
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Table 2. 4 Significant Genes from Gene-level Meta Analysis of HUNT and SardiNIA Exome Chip Data (HDL) 
Gene Burden 
Madsen-
Browning 
VT 
(Actual 
MAF 
Cutoff) 
SKAT
c
 Variants Included
d
 MAF 
Effect 
Sizes 
(SD) 
Single Variant p-
values 
APOC3
b
 2.3×10
-6
 1.9×10
-6
 
6.4×10
-6
 
(6.1×10
-4
) 
4.5×10
-5
 
11:116701560:G:A 4.8×10
-4
 0.959 1.4×10
-3
 
11:116701353:C:T 5.6×10
-4
 1.009 1.5×10
-3
 
11:116701354:G:A 6.1×10
-4
 0.528 5.7×10
-2
 
CETP 6×10
-20
 2.7×10
-3
 
2.4×10
-19 
(3.2×10
-2
) 
1.2×10
-20
 
16:57015091:G:C 3.2×10
-2
 -0.359 1.3×10
-20
 
16:57007387:C:T 4.3×10
-5
 2.241 2.3×10
-2
 
16:56995935:C:G 4.3×10
-5
 -1.572 1.1×10
-1
 
16:57012039:G:A 4.3×10
-5
 -0.803 4.2×10
-1
 
16:57009022:G:A 1.7×10
-4
 0.309 5.3×10
-1
 
16:57015076:G:A 2.2×10
-4
 0.144 7.4×10
-1
 
16:57012094:A:G 4.3×10
-5
 0.182 8.5×10
-1
 
LIPG
b
 1.3×10
-10
 6.7×10
-9
 
4.5×10
-10
 
(9.4×10
-3
) 
1.9×10
-8
 
18:47109955:A:G 9.4×10
-3
 0.375 4.5×10
-8
 
18:47113165:C:T 9.1×10
-4
 0.668 2.3×10
-3
 
18:47109939:G:A 1.7×10
-4
 1.012 3.9×10
-2
 
18:47101838:G:A 4.3×10
-5
 1.000 3.1×10
-1
 
LPL
b
 3.7×10
-11
 4.5×10
-5
 
1.2×10
-10
 
(2.0×10
-2
) 
2×10
-11
 
8:19813529:A:G 2.0×10
-2
 -0.273 1.3×10
-8
 
8:19805708:G:A 1.1×10
-2
 -0.254 7.5×10
-5
 
8:19816888:C:T 1.1×10
-3
 0.234 2.3×10
-1
 
8:19819628:T:G 4.3×10
-5
 0.193 8.4×10
-1
 
LIPC 1.8×10
-4
 1.5×10
-4
 
3.2×10
-5
 
(6.2×10
-3
) 
1.7×10
-7
 
15:58855748:C:T 6.2×10
-3
 0.539 4.9×10
-10
 
15:58837989:G:A 7.4×10
-4
 0.542 2.5×10
-2
 
15:58833993:G:A 3.1×10
-2
 0.054 1.7×10
-1
 
15:58830716:G:A 8.7×10
-5
 0.123 8.6×10
-1
 
15:58853079:A:C 5.9×10
-3
 -0.003 9.8×10
-1
 
15:58860956:G:A 4.3×10
-5
 0.025 9.8×10
-1
 
Significance level 2.84×10-6 was used for reporting significant genes. Non-synonymous, splice, and stop variants with MAF<0.05 were included in 
analysis. 
b: The gene-level p-value is smaller than the p-value for each of the single variants included in the test. 
c: P-values of SKAT were generated using weights suggested in Wu el al. [Wu et al. 2011].  
d: Variants are in the following format: CHR:POS:REF:ALT. 
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Figures  
 
 
Figure 2. 1 Pedigree Structures Used in Simulations 
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Figure 2. 2 Power to Detect Gene-level Association in Family and Population Samples 
All samples had 5,000 individuals. All family samples used the Pedigree50 structure 
(see Figure 1 for details). In every simulation, 10,000 haplotypes were simulated 
and 20% of variants with MAF<0.01 were randomly selected as causal variants, each 
explaining the same amount of trait variance. Then, a subset of simulated 
haplotypes were selected as founder haplotypes, segregated through families 
according to Mendel’s laws, and used to simulate quantitative traits. Power of the 
SKAT test was evaluated using 10,000 simulations and significance level α = 2.5 x 
10-6.  
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Figure 2. 3 Power to Detect Gene-level Association as a Function of Pedigree Structure 
In each simulation, 20% of variants with MAF<0.01 were randomly assigned as 
causal, each explaining the same amount of trait variance. Together, causal variants 
explained 0.5% of trait variance. For comparison, the red line shows the power for 
one variant with frequency of 0.5 and explaining 0.5% of the trait variance. Power of 
the SKAT test was evaluated using 10,000 simulations and significance level α = 2.5 
x 10-6.  
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Figure 2. 4 Power to Detect Gene-level Association When Singletons are Causal 
In each simulation, 10,000 simulated haplotypes were simulated. 20% singletons from these haplotypes were chosen as causal 
variants, together explaining various proportions of trait variance. Trait heritability was 40%. Then, a subset of haplotypes 
were used to seed founder haplotypes in each family sample. Only singletons or private variants were grouped for association 
tests. 10,000 simulations were used to evaluate power in samples of 5,000 individuals (panel A) or 10,000 individuals (panel 
B). See Figure 1 for details of pedigree structures. Power was evaluated in 10,000 simulations using significance level α = 2.5 x 
10-6. 
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Figure 2. 5 Power to Detect at least one of Twenty Causal Genes 
Assuming power to detect association at a specific gene is p and n genes with similar 
effect variants exist, then the power to detect at least one of these is 1-(1-p)n. See 
Figure 2 for power to detect a single gene and additional details of simulation 
settings.  
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Figure 2. 6 Power to Detect at least One of Twenty Causal Genes as a Function of Pedigree 
Structure 
The blue bars show power to detect at least one gene where rare variants explain 
20% of trait variance and 20 such genes exist. The red line shows the power to 
detect at least one common variant with frequency 0.5 that explains 0.5% of trait 
variance when 20 such variants exist. See the legends of Figure 3 for simulation 
settings. See the legends of Figure 5 for calculating power to detect at least one of n 
genes with similar effect variants exist. 
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Supplementary 
 
 
Figure S2. 1 Example Effect Sizes and Variable Explained in Equal Effect Size Model and Equal Variance Model 
80% variants with MAF<0.05 from one simulated population sample of 5,000 individuals were randomly selected as causal. Bars of 
count of variants represent the actual count of causal variants with a certain minor allele frequency.  
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Figure S2. 2 Power of Detecting Association of a Gene when Grouping Rare Variants Using 
Various Frequency Thresholds 
 (A) and (B) Causal variants have the same effect sizes. (C) and (D) Causal variants 
explain the same amount of variance. All samples have pedigree10 structure with 5,000 
individuals. 20% or 50% variants below frequency 1% were selected as causal variants 
that are unidirectional, explaining 2% of trait variance. Then various frequency thresholds 
were used to form the group of variants to test upon. Power was evaluated using 1000 
simulations. 
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Figure S2. 3 Power of Rare Variant Associations in Family Samples and Population 
Samples 
To simulate genotype, 16,000 founder haplotypes of a single variant with certain allele frequency 
were simulated and then gene-dropped to children in family samples (for samples with less than 
8,000 founders, founder haplotypes were randomly selected from the pool of 16,000). Then 
genotypes of each individual were calculated as the count of rare alleles. Null phenotypes were 
simulated at first: in unrelated samples, null phenotypes were random draws from a normal 
distribution; in family samples, null phenotypes were simulated such that family members have 
correlated trait values (with heritability 0.4) based on covariance matrix. Then, final phenotypes 
were modified based on genotype and effect sizes: individuals with rare alleles have phenotypes 
added the amount of effect size ×genotype. A), C), and E) show the power of detecting a single 
variant. B), D), and F) show the power of discovering at least one variant assuming 200 trait-
associated variants of the same frequency and effect size exist. We used α=1x10-8 for power.  
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Figure S2. 4 Power of Discovering a Single Variant of Various Effect Sizes in SardiNIA 
Sample and Population Sample 
SardiNIA sample has 5,916 individuals with both HDL and covariates (age, age2, and sex) 
measured. To compare power with SardiNIA sample, unrelated samples of size 5,916 were 
simulated. To simulate genotypes, 11,832 haplotypes of a single variant were simulated and 
assigned to individuals in the unrelated sample; then, a subset of 7,222 haplotypes were randomly 
selected as founder haplotypes and dropped to children in the SardiNIA sample by Mendelian 
inheritance. Phenotypes were simulated using the same method described in Figure S2.3. Power 
was calculated using 10,000 simulations. A), C) and E) show the power of discovering a single 
variant with frequency 0.0001. B), D), and F) show the power of discovering one variant 
assuming 100 variants of the same frequency and effect size exist. We used α=1x10-8 to 
determine power. 
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Figure S2. 5 QQ Plots of HUNT, SardiNIA, and Meta-analysis Single Variant Associations 
Variants with HWE p-value < 1.0e-05 or call rate < 0.95 were excluded from the analyses. 
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Figure S2. 6 Manhattan Plots of HUNT, SardiNIA, and Meta-analysis Single Variant 
Associations  
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Figure S2. 7 HUNT SardiNIA and Meta-analysis Gene-level Associations QQ Plots 
 
Variants with MAF<0.05 were grouped for gene-level tests. Variants with HWE p-value < 1.0e-
05 or call rate < 0.95 were excluded.  
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Figure S2. 8 Manhattan Plots for HUNT and SardiNIA Gene-level Associations 
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Figure S2. 9 QQ Plots Generated by Various Tools from Various Family-based Gene-level Tests Analyzing a Simulated Data Set 
 
A), B), C), and D) are from VT and un-weighted and Madson-Browning-weighed burden and tests. E), F), G), and H) are from family-
based SKAT and kernel tests. 4000 genes of 1k bp were simulated in a family sample with 10,000 individuals in 1000 families. A 
quantitative trait was simulated under the null. All analyses used pedigree-based kinship matrix. Davies method was used to calculate 
pvalue from SKAT test in famSKAT.
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Figure S2. 10 Power Comparison among Various Methods and Implementations 
 
1000 simulations of 5,000 individuals in 500 families were used to evaluate power for 
each method and implementation. A gene of 1000 base-pair explaining 1% trait variance 
was simulated in each data set. 50% variants with MAF<0.05 were selected as causal 
variants. In bidirectional scenario, half causal variants were selected to have opposite 
effects.  
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Table S2. 1 Type I Error of Gene-level Association Tests 
 
 
a. MB is the Madsen-Browning weighted burden test. 
b. SKAT uses the Beta(MAF,1,25) density weight. 
c. 95% confidence interval calculated based on 5,000,000 simulations.  
All estimates are within 95% confidence interval or below the lower 
level of the 95% confidence interval.  
 
  
Pedigree N Method 0.05 1×10
-4
 1×10
-5
 2.5×10
-6 
95% Confidence Intervals
c
  
(0.0498, 
0.050) 
(9.12x10
-5
, 
1.09x10
-4
) 
(7.23x10
-6
, 
1.28x10
-5
 
(1.11x10
-6
, 
3.89x10
-6
) 
Pedigree10 1000 Burden 0.050 9.06×10
-5
 7.84×10
-6
 1.67×10
-6
 
Pedigree10 1000 MB
a
 0.050 9.19×10
-5
 6.84×10
-6
 1.67×10
-6
 
Pedigree10 1000 VT 0.050 7.54×10
-5
 7.34×10
-6
 1.17×10
-6
 
Pedigree10 1000 SKAT
b
 0.050 7.99×10
-5
 8.51×10
-6
 2.50×10
-6
 
Pedigree10 5000 Burden 0.050 9.95×10
-5
 8.00×10
-6
 1.75×10
-6
 
Pedigree10 5000 MB 0.050 9.38×10
-5
 8.25×10
-6
 1.00×10
-6
 
Pedigree10 5000 VT 0.050 8.20×10
-5
 8.25×10
-6
 1.75×10
-6
 
Pedigree10 5000 SKAT 0.050 8.73×10
-5
 9.00×10
-6
 2.50×10
-6
 
Pedigree50 1000 Burden 0.049 8.43×10
-5
 7.00×10
-6
 1.33×10
-6
 
Pedigree50 1000 MB 0.049 8.02×10
-5
 6.83×10
-6
 1.50×10
-6
 
Pedigree50 1000 VT 0.050 8.03×10
-5
 6.83×10
-6
 1.83×10
-6
 
Pedigree50 1000 SKAT 0.048 8.28×10
-5
 6.33×10
-6
 1.33×10
-6
 
Pedigree50 5000 Burden 0.050 1.01×10
-4
 1.02×10
-5
 1.50×10
-6
 
Pedigree50 5000 MB 0.050 9.95×10
-5
 9.00×10
-6
 1.75×10
-6
 
Pedigree50 5000 VT 0.050 9.03×10
-5
 8.75×10
-6
 2.25×10
-6
 
Pedigree50 5000 SKAT 0.050 9.83×10
-5
 8.50×10
-6
 2.50×10
-6
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Table S2. 2 Allele Counts in Population and Family Samples by Frequency 
 
Sample 
N 
(Founder) 
Allele Counts (StDev)  
MAF=            0.05 0.01 0.005 0.001 
Unrelated 5000 (5000) 500.2 (21.4)  100.2 (9.7) 50.0 (6.7) 10.0 (3.2) 
Nuclear4 5000 (2500) 499.8 (32.1) 100.3 (14.6) 49.9 (10.7) 10.0 (4.8) 
Pedigree10 5000 (2000) 499.2 (38.3) 100.7 (17.7) 50.1 (12.7) 9.8 (5.6) 
Pedigree25 5000 (1600) 501.1 (48.8) 99.5 (22.3) 50.0 (16.1) 10.0 (7.2) 
Pedigree50 5000 (800) 503.21 (69.1) 99.8 (31.8) 49.9 (23.0) 10.0 (10.3) 
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Table S2. 3 Summary Statistics for HUNT and SardiNIA HDL Phenotype 
 
 
  
Sample 
Size 
Male Female 
N Mean Median Min Max 
Age 
(mean, 
median) N Mean Median Min Max 
Age 
(mean, 
median) 
HUNT 5637 3717 47.9 46.4 19.3 116.0 62,61 1920 56.7 54.1 23.2 139.2 70,68 
SardiNIA 5916 2506 58.7 57.1 21.3 147.7 42,44 3410 68.4 66.9 28.0 135.1 42,43 
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Table S2. 4 Count of Variants in HUNT and SardiNIA Exome Chip Data 
 
 
[0,0.01] (0.01,0.05] (0.05,1] Total 
HUNT 63,202 9,094 21,535 93,831 
SardiNIA 41,986 9,699 25,143 76,828 
Total 117,958
a
 
 
a. This is the total number of sites that are polymorphic in the pooled HUNT and 
SardiNIA sample.  
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Table S2. 5 Count of Shared Variants in HUNT and SardiNIA Exome Chip Data 
 
  
HUNT 
[0,0.01] (0.01,0.05] (0.05,1] Total 
S
a
rd
iN
IA
 
[0,0.01] 20,149 3,646 212 24,007 
(0.01,0.05] 2,817 3,631 1,534 7,982 
(0.05,1] 168 1,345 19,198 20,711 
Total 23,134 8,622 20,944 52,700
a
 
 
a: This is the number of shared variants between HUNT and SardiNIA ExomeChip data.  
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Table S2. 6 Count of Non-Shared Variants in HUNT and SardiNIA Exome Chip Data 
 
MAF [0,0.01] (0.01,0.05] (0.05,0.5] Total 
HUNT 40,068 472 590 41,130
a
 
SardiNIA 17,979 1,717 4,432 24,128
b
 
Total 65,258
c
 
 
a: this is the number of variants that are polymorphic in HUNT but not in SardiNIA. 
b: this is the number of variants that are polymorphic in SardiNIA but not in HUNT. 
         c: the count of variants that are monomorphic in one study, but polymorphic in the other. 
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Table S2. 7 Time Usage and Key Features of Various Tools 
  
Run 
Time 
Peak 
Memory 
Use Kinship Options Input Files Implementation 
famrvtest 1.5 hrsa 1.3G 
Pedigree-based 
kinship or empirical 
kinship estimated 
from genotype 
within tool 
VCF or 
Merlin 
PED/DAT file 
C++ command 
line software 
famskat 
798 
hrsb* 3.9G 
Pedigree-based 
kinship generated by 
kinship R package 
summarized 
genotype 
matrix R function 
pedgene 20 hrs* 4.4G 
Pedigree-based 
kinship generated by 
kinship2 R package  
summarized 
genotype 
matrix R package 
FFBSKAT 13 hrsc* 22G 
Pedigree-based 
kinship generated by 
kinship2 R package 
or estimated from 
genotype by 
GenABEL 
summarized 
genotype 
matrix R package 
 
All time collections were based on one CPU time analyzing 4000 genes of 1000 base-pair 
in a family sample of 10,000 individuals in 1000 families.  
a. Time used for generating both burden and SKAT results starting from a VCF file.  
b. famSKAT only allows a gene per run, thus the total run time is linear to number 
of genes analyzed. Time to analyze one gene is 2.6 minutes.  
c. 9.9 hours were used to fit the linear mixed model under the null. 3.3 hours were 
used for calculating SKAT association statistics and p-values.  
*. Time usage does not include summarizing raw data into usable genotype matrix.  
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CHAPTER 3: ASSOCIATION AND META-ANALYSIS METHODS FOR 
CHROMOSOME X 
Introduction 
The X chromosome contains 5% information of the human genome sequence, but 
contributes fewer GWAS findings than even chromosome 21 [Wise et al. 2013], which is 
considerably smaller. This is mostly because appropriate statistical methods and tools are 
sparse making analysis inconvenient, especially for family samples. Although low 
frequency and rare variant association analysis is becoming routine for GWAS, there are 
limited tools and methods for gene-level and rare variant association on the X 
chromosome. 
 
Many work on X chromosome association methods for quantitative traits have been 
published. The work of Clayton et al. [Clayton 2008] proposed a score test for single 
variants on X chromosome in unrelated individuals.The XQTL approach [Zhang et al. 
2009]uses a mixed model including separate random effects for X chromosome and the 
autosomes while modeling X-linked marker association as a fixed effect, which can be 
further decomposed into within family and between family contributions to overcome 
population stratification [Abecasis et al. 2000; Fulker et al. 1999]. However, this method 
is limited to nuclear families, and the decomposition naturally causes loss of power. 
MINX [Abecasis 2002], MERLIN in X, uses a variance component approach to model 
polygenic effects from both autosome and X chromosome and provides score and 
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likelihood ratio tests for X-linked marker associations, which allows analysis with small 
arbitrary pedigrees. We are also aware that much work has been done on qualitative traits 
X-linked marker associations in family samples [Chung et al. 2007; Clayton 2008; 
Thornton et al. 2012; Zhang et al. 2008; Zheng et al. 2007], and X-linked QTL linkage 
analysis methods have been extensively studied and implemented in tools that are now 
widely used [Abecasis et al. 2002; Almasy and Blangero 1998; Ekstrom 2004; Lange and 
Sobel 2006]. We extend this prior work, which focused on linkage analysis methods and 
also on the analysis of single variants. Here, our work focuses on gene-level association 
and meta-analysis methods for quantitative trait in families and also on enabling practical 
strategies for modeling and controlling for population structure. All our methods are 
naturally applicable to unrelated individuals – since these are simply a special sampling 
strategy where each family includes a single individual. 
 
In this paper, we extend currently popular gene-level association and meta-analysis 
methods, SKAT, burden and VT tests, to X chromosome rare variants analysis. Our 
methods build upon the recent insight that gene-level association test statistics and meta-
analysis statistics can be reconstructed from single-variant summary statistics [Feng et al. 
2015; Liu et al. 2014]. Since most genes on X chromosome are down regulated through 
X-inactivation, such that only one “randomly” selected allele is expressed in cell or cell 
lineage [Chow et al. 2005], our methods are designed to account for this: basically, they 
assume that males hemizygous for an allele A will have the same phenotype as a female 
homozygous for A/A and that the phenotype of heterozygous females will be 
intermediate relative to the phenotype of opposite homozygotes. We evaluate type I error 
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and power of our approach using simulated data and 74 quantitative traits collected from 
SardiNIA study [Pilia et al. 2006].  
 
Method  
In this section, we describe a variance component model to handle relatedness among 
individuals and how to reconstruct gene-level association statistics from single variant 
summary statistics and covariance matrices, for both single study and meta analysis. 
Then, we summarize how we evaluated our method under the null and alternative 
hypothesis and the SardiNIA study dataset where we evaluated real life performance of 
our approach.  
Variance Component Model 
Given a sample of n individuals, we model quantitative trait values y as:  
𝐲 = 𝐗𝛃 + βsex𝐒𝐞𝐱 +  𝐠 + 𝐠𝐗 + 𝛜 
Here, Sex is the indicator variable vector encoding sex for each sample, βsex is the effect 
size for sex, X is the design matrix with relevant clinical covariates and intercept, 𝛃 is the 
vector of effect sizes of the covariates, g and gX are vectors of random effects modeling 
additive genetic effects from the autosomes and the X chromosome respectively, and 𝛜 is 
the vector of random error. We assume 𝛜 follows a multivariate normal distribution with 
mean 0 and covariance 𝐈σe
2. We also assume the autosomal and X chromosome genetic 
effects g and 𝐠𝐗 follow multivariate normal distributions with mean 0 and covariance 
2σg
2𝐊 and 2σgX
2 𝐊𝐗 , respectively. Matrices K and KX summarizes kinship coefficients 
from the autosomes and X chromosome[Lange 1997]. σg
2  is a  non-negative number 
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describing the autosomal polygenic variance contribution. σgX
2  is a  non-negative number 
that quantifies the X chromosome’s polygenic contribution to trait variance. As 
systematically described in previous works [Kent et al. 2005; Zhang et al. 2009], 
assuming complete female X-inactivation, variance explained by X-linked polygenic 
effect in females (σgX
2 ) will be half of the variance explained in males (2σgX
2 ). In the 
overall sample, the variance explained by X-linked polygenes is (2 − r)σgX
2  where r is the 
proportion of females in the sample, and total phenotypic variance equals σg
2 +
(2 − r)σgX
2 + σe
2 . Mean and covariance of y are E(𝐲) =  𝐗𝛃  and Cov(𝐲) = 2σg
2𝐊 +
2σgX
2 𝐊𝐗 + 𝐈σe
2 . Parameter estimates ?̂? , σg2̂ , σgX
2̂  and σe2̂  are obtained using maximum 
likelihood. Although, in simple models of X-inactivation, males and females can have the 
same mean, we strongly recommend including sex as a covariate in the model to account 
for possible mean differences between the sexes.  
 
Kinship coefficient is the probability of randomly drawing two chromosomes that are 
identical by decent (IBD) from a pair of individuals. We consider two approaches for 
estimating kinship matrices K and KX. One approach uses known pedigree structure to 
calculate the expected kinship, an alternative approach uses marker genotypes across the 
entire genome to calculate observed kinship. Since males inherit X chromosome only 
from their mothers, the values and algorithms for KX are different from those for K. For 
example, for non-inbred individuals, the self-kinship coefficients for are 1 (for males) and 
0.5 (for females) on chromosome X; they are 0.5 (for both sexes) on autosomes. 
Estimating KX between family members was fully discussed in [Kent et al. 2005; Lange 
1997] and summarized in [Zhang et al. 2009].  
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Our alternative method estimates kinship using the Balding-Nicols empirical estimator 
[Astle and Balding 2009], ?̂? =
1
𝑣
∑
(𝐆𝐢−2𝑓𝑖𝟏)(𝐆𝐢−2𝑓𝑖𝟏)
𝐓
4𝑓𝑖(1−𝑓𝑖)
𝑣
𝑖=1  (here, v is the count of variants, 
𝐆𝐢  is a genotype vector where each element encodes the number of observed minor 
alleles in a particular individual, and fi is the estimated minor allele frequency for the i
th
 
variant). We estimate KX using this equation, but coding female genotypes as 0,1, or 2 
(depending on the number of minor alleles), and male genotypes as 0 or 2 (depending on 
presence or absence of the minor allele). This method allows us to quantify relatedness 
between apparently unrelated individuals and also allows for stochastic variation among 
pairs of individuals with the same degree of relatedness based on available pedigree data.   
Association and Meta-analysis Methods 
As previously described in our work [Feng et al. 2015], autosomal gene-level association 
test statistics can be reconstructed from single variant summary statistics and their 
covariance matrix. In this section, we apply the same idea to gene-level association and 
meta-analysis statistics for the X chromosome. 
 
We first calculate use a score test for each variant [Chen and Abecasis 2007] and 
compute summary statistics and their covariance.  The score statistic for the i
th 
variant is 
Ui = (𝐆𝐢 − 𝐆𝐢)
T?̂?−1(𝐲 − 𝐗?̂?) where Gi is the genotype vector of this variant, ?̂? is the 
estimated covariance matrix of phenotype 𝐲, and ?̂? is the estimated fixed effect of clinical 
covariates. The covariance matrix of m score statistics of m variants in a gene is 𝐕 =
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(𝐆 − 𝐆)T(?̂?−1 − ?̂?−1𝐗(𝐗𝐓?̂?−𝟏𝐗)
−𝟏
𝐗𝐓?̂?−𝟏)(𝐆 − 𝐆)  where G is the 𝑛 × 𝑚  genotype 
matrix. Under the null, score test of i
th
 variant Ti =
Ui
√𝑉𝑖𝑖
~N(0,1) asymptotically.  
 
Burden and Variable Threshold (VT) tests evaluate a similar model  
𝐲 = βsex𝐒𝐞𝐱 + 𝐗𝛃 + γ(𝐆 − 𝐆)𝐰 + 𝐠 + 𝐠𝐗 + 𝛆 
where γ is the fixed effect of the tested gene and null hypothesis is H0: γ = 0. The burden 
score test statistic for an X-lined gene can be reconstructed from U and V as Tburden =
𝐰𝐓𝐔
√𝐰𝐓𝐕𝐰
~N(0,1) asymptotically. w is the vector of weights for the m variants in a gene. 
The VT test uses the maximum absolute burden score statistics over all possible 
frequency thresholds as the test statistic TVT = maxF |TburdenF|, and TburdenF =
𝛟𝐅
𝐓𝐔
√𝛟𝐅
𝐓𝐕𝛟𝐅
 
where 𝛟𝐅
𝐓  is a vector of 0s and 1s indicating if a variant is included by a specific 
frequency threshold Null distribution and p-value evaluation has been described in detail 
in [Lin and Tang 2011; Liu et al. 2014]. 
 
Sequence Kernel Association Test (SKAT) evaluates a different model 
𝐲 = 𝐗𝛃 + βsex𝐒𝐞𝐱 + 𝛄(𝐆 − 𝐆) + 𝐠 + 𝐠𝐗 + 𝛆 
where γi is effect size of the i
th 
variant in a gene and is randomly distributed with mean 0 
and variance 𝜏𝑤𝑖 . The null hypothesis is H0: τ = 0 . The SKAT statistic is TSKAT =
𝐔𝐓𝐖𝐔 where 𝐖 = diag(w1, w2, … , wm) is a diagonal matrix of weights for each variant 
in a gene. Null distribution of TSKAT and evaluation of significance was thoroughly 
described in [Chen et al. 2013; Wu et al. 2011]. 
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To reconstruct gene-level meta-analysis statistics, we define single variant score statistics 
for meta-analysis as Umetai = ∑ Uik
s
k=1  and Vmetaij = ∑ Vij,k
s
k=1 , where s is the total 
number of studies,  Uik and Vij,k are score statistics and elements of covariance matrix 
from study k [Liu et al. 2014]. Then, gene-level association statistics can be established 
using the same method as described above for a single study. 
Simulations  
To evaluate our variance component model, we simulated quantitative traits under the 
null. We used three-generation pedigrees with a female to male ratio of 1:1 (see Figure 
S1 for pedigree structure).  Then the maximum likelihood estimates of variance 
components were averaged over 1,000 simulations and compared with the true generating 
values. To evaluate power, we simulated 10,000 haplotypes of 1,000 base-pair sequences, 
which is close to the length of an average protein coding sequence in humans. We 
simulated the haplotypes using ms [Hudson 2002] and a demographic model calibrated to 
mimic European population history [Adams and Hudson 2004; Novembre et al. 2008], 
and then we randomly selected 20% variants with frequency <0.01 as causal variants and 
defined effect sizes so that they altogether explained various amount of trait variance. We 
then randomly assigned founder haplotypes from the pool of haplotypes generated by ms, 
assigning one haplotype to each male founder and two to each female founder. We then 
successively sampled haplotypes for each descendant according to Mendel’s Laws. When 
evaluating type I error, autosomal and X-linked polygenic effects, together with random 
error, were simulated. When evaluating power, causal gene effects were simulated on top 
of these.. We note autosomal heritability h2 =
σg
2
Var(y)
, and X heritability hX
2 =
σgX
2
σg
2+σgX
2 +σe
2. 
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SardiNIA Study 
To evaluate our method in real data, we used exome chip data from the SardiNIA 
[Giorgio et al. 2014; Pilia et al. 2006] study, which genotyped 6,602 individuals. We 
analyzed 74 cardiovascular and personality quantitative traits, adjusted for age, sex and 
squared age, on 81,559 variants on exome chip where 1,543 variants were from 
chromosome X. Among X-linked variants, 817 had MAF<.01, 1,012 had MAF<.05. 
Among 79,980 autosomal variants, 44,557 had MAF<.01, and 53,742 had MAF<.05. 
Genotypes were called using the Illumina GenCall algorithm in combination with zCall 
V2.2. Detailed QC procedures can be found in [Giorgio et al. 2014].  
Results  
Accuracy of Heritability Estimates 
To calibrate our variance component model, we simulated quantitative traits under the 
null where autosomal heritability were either 40% or none and X heritability varied from 
5% to 40%, in samples of 1,000 individuals with a three-generation pedigree with 10 
individuals in each family and sex ratio 1:1 (see Figure S1). We then averaged variance 
component estimates over 1,000 simulations for each setting. Table 1 shows that when 
both autosomal and X chromosomal heritability are not zero, all 95% confidence 
intervals include true values. Table 1 also shows that when true X heritability was zero, 
including X variance component in the model caused minimal false attribution of 
variance (1%) to chromosome X; this is expected since variance components are always 
estimated as positive. When the autosomal heritability was zero (Table S1), autosomal 
variance component captured a minimal amount of variance (<2% among all scenarios), 
and X heritability estimates were less than 1% smaller than true simulated values.  
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Type I error 
To evaluate type I error, we simulated quantitative traits under the null in samples of 
5,000 individuals in pedigree10 (see Figure S1) together with 2,000 genes under the null. 
Figure 2 and Figure S2 show that when X heritability was 10%, regardless autosome 
heritability was zero or 40%, QQ plots from all of our four gene-level tests were under 
control. Figure S3 shows that if X heritability was 10% but we ignored the X variance 
component in the model, then QQ plot was really out of calibration under the null.  
Power and Proportion of Females 
Assuming complete X-inactivation in female, additive genetic effect from a causal gene 
from male samples has variance that is twice of that from female samples [Kent et al. 
2005]. This leads to a hypothesis that including more males in a sample has larger 
association power to detect a single variant or a gene of the same allelic effect size in 
both male and female. To evaluate this hypothesis, we simulated quantitative traits of 
5,000 unrelated individuals with different proportion of females in the sample and genes 
with 1,000 base-pair length and pre-defined causal variants (20% variants with 
MAF<.01) and effect sizes such that the gene explains 1% of trait variance in female 
samples, and performed burden test grouping variants with MAF<.01. Figure 2 confirms 
that, although larger male proportion means less causal variants collected in a sample, 
more males in a sample leads to larger association power to detect a gene explaining the 
same amount of variance in females. In a more extreme situation, all-male sample has 
three times more power (26%) than all-female sample (5%) to detect a gene explaining 
1% of trait variance in females.  Figure S4 shows similar power advantage in all-male 
sample when the variance explained by a gene in females varied from 0.5% to 2%.  
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Autosome vs. X Chromosome Power  
In practice, if a causal gene has the same set of causal variants and effect sizes, the power 
should be identical if the gene is autosomal compared to if the gene is X-linked and the 
sample contains only female. This is because causal variants have the same chances to be 
sampled in both situations and following the same segregation pattern in families. 
However, if there are males in a sample, then power is expected to be larger if the gene is 
X-linked than if the gene is autosomal. As before, we simulated 10,000 haplotypes of a 
gene with 1,000 base-pairs and randomly selected 20% variants with MAF<.01 to be 
causal and calculated effect sizes such that the gene explains 0.5%-2% trait variance as if 
the gene was autosomal (the same amount of variance explained in females if the gene 
was X-linked). We simulated quantitative traits with 40% autosomal heritability and 10% 
X heritability in families with Pedigree10 (Figure S1) where half of the samples were 
male. Figure 3 shows that there was much larger power to detect an X-linked gene than 
an autosomal gene explaining the same amount of variance. For example, when the gene 
explained 1% trait variance, power to detect an autosomal gene of such effect was 5% 
while power to detect such an X-linked gene was 12%. Figure S5 shows similar power 
advantage over an X-linked gene with 0% autosomal heritability and 10% X heritability 
compared with an autosomal gene explaining the same amount of variance with 40% 
autosomal heritability. 
SardiNIA results 
To demonstrate our methods using real data, we analyzed exome chip data from 
SardiNIA study on multiple cardiovascular and personality quantitative traits using both 
single variant and gene-level tests. Empirical kinship matrices from autosome and X 
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chromosome were estimated from genotype of variants with MAF>0.05. Seventy traits 
have genomic controls between 0.95 and 1.05. There are four traits with genomic control 
(GC) greater than 1.05 where the largest is 1.08. Among all traits, X chromosome have 
substantial amount of contribution to trait variance in G6PD level and HbA1C, with X 
heritability 27% and 10% individually, whereas the others showed X heritability of <4%. 
70 traits showed greater than zero autosomal heritability over a range of 5%-56%. Figure 
4 uses G6PD level as an exemplar trait showing that type I error and GC were under 
control. Table 2 reports signal detected from single variant tests of 1,543 polymorphic 
sites from X chromosome from exome chip using significance level 6.13x10
-7
 according 
by Bonferroni correction with 81,566 variants tested. All signal belong to three variants 
where two of them were rare with frequency <.01, and these variants were associated 
with twelve traits. Except G6PD level, all other eleven traits have only one significant 
association. Conditional analysis conditioning on the top signal in G6PD level, which is a 
relatively common variant with frequency 0.08 and p-value 6.7x10
-77
,
 
showed 
strengthened significance from 1.3x10
-24
 to 4.4x10
-26
 for the other significant rare variant 
with frequency 0.9%. This shows that this rare variant with position 153774337 on X 
chromosome with major allele C and minor allele A is not a shadow of the common 
variant nearby with the strikingly small p-value. Condition upon this rare variant obtained 
a smaller p-value for the common variant at position 153762634 with major and minor 
alleles G and A also. The conditional analysis shows that these two variants are likely to 
be independent signals instead of being shadows of each other.   
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Gene-level tests of all quantitative traits detected the association of gene G6PD with 
G6PD level using significance level 2.8x10
-6
 as shown in Table 3. All three variants 
included in gene-level tests had MAF<.01 and all had negative effects. Although the 
single variant at position 153774337 with frequency .009 and effect size of -0.8 largely 
drives the signal from gene-level tests (p=***), the burden p-value 7.8x10
-29
 is smaller 
than any of the single variant p-value. The other two extremely rare variants with 
frequency 3x10
-4
 and 4x10
-4
 both had larger effect sizes than the variant that dominates 
the signal. P-value from VT test was closer to burden p-value but a little less significant 
due to tradeoff of multiple testing. SKAT p-value was less significant compare to burden 
and VT tests in this example, since all variants had the same direction of effect. Table 3 
also shows that condition upon the common variant with the most significant p-value 
from single variant test at position 153762634 (see Table 2) leads to an even smaller p-
value for all four gene-level tests. This is evidence showing that the gene-level test signal 
of G6PD is not due to shadowing the single common significant variant of strikingly low 
p-value nearby. Analyses that condition on the most significant variant at position 
153774337 included in the gene with frequency 0.009 had a much less significant p-
value, suggesting that the gene-level test signal was mostly driven by this variant. 
However, all four conditional p-values from four gene-level tests was smaller than either 
of the rare variant included in the test, which shows synergy of these two low-frequency 
variants contributing toward the significance of these gene-level tests.  
Conclusion and Discussion  
In this paper, as an extension of our previous work [Feng et al. 2015], we described gene-
level association tests, including burden, variable threshold and sequence kernel 
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association tests that can be reconstructed from summary statistics and their covariance 
matrices from single-variant scan. This approach allows fast computation for multiple 
gene-level tests and flexible grouping strategies without analyzing raw data repeatedly. 
This also extends to powerful meta-analysis approach where raw data sharing is 
impossible. We also demonstrated that for an X-linked gene with same effects, more 
males in a sample have larger power; and there is larger power to detect an X-linked gene 
than an autosomal gene with same effect sizes.   
 
As pointed out by [Kent et al. 2005], assuming complete X-inactivation, male variance is 
twice of female and male and female have equal mean. Using this simple relationship, we 
use a variance component model with three variance components accounting autosomal, 
X chromosomal, and non-shared environmental contributions. We also described that 
empirical relationship from X chromosome can be estimated using genotypes from X-
linked common variants. This expands our methods to handling possible cryptic 
relatedness, relatedness when pedigree structure is not known, distant relatedness, and 
possible population structure and provide more calibrated results under the null.  
 
However, like any other method, our approach has assumptions that can be violated such 
that the model is not valid. For example, residual correlation may still exit after modeling 
relatedness from autosome and X chromosome because of other causes of phenotypic 
similarity such as shared-environment. If we fail to take account variance contribution of 
these extra causes in the model, and they happen to be quite large, then the model that we 
proposed might be off calibration. In this sense, checking QQ plots for any evidence of 
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inflated or deflated type I error after analysis is always recommended before making any 
conclusions.  
 
The assumption of complete X-inactivation might not always be true either. However, as 
pointed out in [Carrel and Willard 2005; Payer and Lee 2008], incomplete X-inactivation 
is often the basis of various degrees of female X chromosome anomaly. As discussed in 
[Ober et al. 2008], if the trait of interest is not about X chromosome abnormalities in 
female, then the assumption of complete X-inactivation is valid, but we recommend 
excluding samples with this anomalies from analysis when feasible.  It is also worth to 
point out that, in the situation of incomplete X-inactivation, female and male might have 
different mean. In this case, sex should be included as a covariate in the model.  
 
There are other assumptions that could be violated in real data analysis. For example, 
allele frequencies might be different in male and female due to many causes, such as 
heterogeneous ethnicity and sequencing or genotyping error. Many other reasons might 
also cause difference in mean between sexes, for example men and women differ 
naturally in average height, BMI and some personality traits. Thus, we recommend to 
always add sex as a covariate to account for the possible difference in mean. Equal effect 
sizes in male and female might also be violated due to regulatory difference between 
sexes in some traits. If there is previous knowledge showing that this is true, then the 
interaction between sex and genotype should be included in the model and sex should be 
included as a covariate. 
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Finally, although this paper mainly focuses on methods for family samples, population 
samples can be considered a special case of family sample and our methods and tools are 
feasible to samples of unrelated individuals. Our method has been implemented in 
RAREMETAL, a freely available software that supports multiple platforms including 
Linux, MAC, and Windows. The documentation, source code and executable can be 
downloaded in the following: 
http://genome.sph.umich.edu/wiki/RAREMETAL_Documentation 
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Tables 
 
Table 3. 1 Autosomal and X Chromosomal Heritability Estimates Under the Null 
Polygenic 
Source 
True 
Heritability 
Mean 
Estimates SE 
Lower 95% 
Confidence 
Level 
Upper 95% 
Confidence 
Level 
Chr. X 0.05 0.05 0.0007 0.050 0.052 
Autosome 0.40 0.40 0.0012 0.396 0.401 
Chr. X 0.15 0.15 0.0008 0.149 0.152 
Autosome 0.40 0.40 0.0012 0.396 0.401 
Chr X 0.10 0.10 0.0008 0.099 0.103 
Autosome 0.40 0.40 0.0013 0.397 0.402 
Chr. X 0.25 0.25 0.0008 0.249 0.252 
Autosome 0.40 0.40 0.0012 0.396 0.401 
Chr. X 0.20 0.20 0.0008 0.199 0.203 
Autosome 0.40 0.40 0.0012 0.396 0.401 
Chr. X 0.35 0.35 0.0009 0.349 0.352 
Autosome 0.40 0.40 0.0012 0.396 0.401 
Chr. X 0.30 0.30 0.0008 0.299 0.302 
Autosome 0.40 0.40 0.0012 0.396 0.401 
Chr. X 0.40 0.40 0.0009 0.399 0.402 
Autosome 0.40 0.40 0.0012 0.397 0.402 
Chr. X 0.00 0.01 0.0004 0.007 0.009 
Autosome 0.40 0.39 0.0009 0.388 0.392 
 
Each grid represents a simulation setting with a certain combination of autosomal 
heritability (h
2
) and X chromosomal heritability (hx
2
). Results were summarized from 
1,000 simulations.  
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Table 3. 2 Single Variant Hits on Chromosome X from SardiNIA Quantitative Traits 
Association Tests 
Trait GC* Chr:Pos:A1:A2
$
 N MAF
@
 
Effect Size 
(SD)
#
 
p-value 
Conditional 
p-value** 
G6PD Level 0.99 X:153762634:G:A 6613 0.08 -1.19 6.7x10
-77
 2.3x10
-78 
G6PD Level 0.99 X:153774337:C:A 6613 0.009 -0.79 1.3x10
-24
 4.4x10
-26
 
HbA1C 1.03 X:153762634:G:A 6434 0.08 -0.74 1.1x10
-58
 
 
RBC 1.03 X:153762634:G:A 6724 0.08 -0.29 9.9x10
-20
   
Bilirubin, 
total 
0.96 X:153762634:G:A 6198 0.08 0.32 2.4x10
-18
 
 MCV 1.02 X:153762634:G:A 6724 0.08 0.27 9.9x10-15   
Serum Iron 0.96 X:153762634:G:A 6769 0.08 0.22 1.6x10
-12
 
 MCH 1.03 X:153762634:G:A 6724 0.08 0.23 3.4x10-11   
BMI 1.05 X:153036439:A:G 6770 0.0003 2.87 1.0x10
-8
 
 Waist 1.06 X:153036439:A:G 6770 0.0003 2.53 6.6x10-8   
Weight 1.03 X:153036439:A:G 6770 0.0003 2.68 4.4x10
-8
 
 Bilirubin, 
fractionated 
1.01 X:153762634:G:A 6198 0.08 0.18 2.2x10
-8
   
Ferritin 0.98 X:153762634:G:A 4936 0.09 0.17 2.3x10
-7
   
 
6.13x10
-7
 was used as p-value cutoff for hits. Table is sorted by smallest p-value and trait.  
*GC represents genomic control.  
$
A1 is the major allele, and A2 is the minor allele.  
@
MAF is the minor allele frequency and was calculated from founders. 
#
Effect sizes of minor 
allele were measured in standard deviations.  
**If there are more than one significant variants for a trait, then conditional analysis was 
performed. Only G6PD level has two hits. The first p-value was from conditional analysis 
conditioning on X:153774337:C:A, and the second p-value was p-value from conditioning on 
X:153762634:G:A. 
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Table 3. 3 Gene-level Association and Conditional Analysis of SardiNIA G6PD Level 
Gene 
Variants 
Included
$
 
MAF 
Effect 
Size 
(SD)* 
P-value* 
Gene-level Test p-value 
Burden MB SKAT VT 
Unconditioned 
G6PD 
X:153761811:C:G 0.0004 -1.24 1.0x10
-4
 
7.8x10
-29
 1.3x10
-21
 4.0x10
-25
 2.3x10
-28
 X:153764217:C:T 0.0003 -1.18 9.8x10
-3
 
X:153774337:C:A 0.009 -0.79 1.3x10
-24
 
Condition on X:153762634:G:A
&
 
G6PD 
X:153761811:C:G 0.0004 -1.22 1.2x10
-4
 
2.3x10
-30
 2.1x10
-22
 1.3x10
-26
 6.8x10
-30
 X:153764217:C:T 0.0003 -1.22 8.0x10
-3
 
X:153774337:C:A 0.009 -0.81 4.4x10
-26
 
Condition on X:153774337:C:A 
G6PD 
X:153761811:C:G 0.0004 -1.21 1.4x10
-4
 
3.2x10
-6
 3.2x10
-6
 2.2x10
-5
 5.6x10
-6
 X:153764217:C:T 0.0003 -1.24 6.7x10
-3
 
X:153774337:C:A 0.009 
  
 
*These are results from single variant tests. Effect sizes are for minor alleles. 
$Variants included are in the format of Chr:Pos:MajorAllele:MinorAllele. 
&
X:153762634:G:A is the variant that is most significant from single variant test for 
G6PD (See Table 3.2) with frequency 0.08.  
G6PD levels were quantile normalized before association analysis.  
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Figures 
 
Figure 3. 1 QQ Plots under Null with both Autosomal and X Contribution to Variance 
 
 
Quantitative traits were simulated in 5,000 individuals with pedigree10 (see Figure 
S3.1 for structure) under the null model. Autosomal heritability was 40% and X 
heritability was 10%. 2,000 genes were simulated starting from founder haplotypes 
and then gene-drop to children along pedigrees. Variant with frequency <0.01 were 
grouped for four gene-level tests and then QQ plots were generated based on the 
obtained p-values.  
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Figure 3. 2 Power and Proportion of Females in a Sample 
 
Power was averaged over 1,000 simulations. 10,000 haplotypes for a gene with 1k 
base-pair were simulated. Then 20% variant with frequency <0.01 were assigned to 
be causal. Effect sizes of causal variants were calculated such that causal variants 
altogether explain 1% trait variance in females. Then quantitative traits of 5,000 
unrelated individuals were simulated based on causal effects and with various 
proportion of female samples. Simple burden test was performed on each simulated 
data set.  
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Figure 3. 3 Power to Detect an Autosomal Gene and an X-linked Gene 
 
10,000 haplotypes with1k base-pairs in length were simulated. 20% variants with 
frequency <0.01 were selected to be causal and effect sizes calculated such that the 
gene explains 0.5%-2% proportion of trait variance in females. Founder haplotypes 
of 5,000 individuals with pedigree structure shown in Figure S3.1 were randomly 
selected from the pool of haplotypes. Children haplotypes were gene-dropped from 
parents haplotypes. Quantitative traits were simulated with 40% autosomal 
heritability (for autosomal associations) and 10% X heritability plus 40% autosomal 
heritability (for X-linked associations) together with causal gene effects. 
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Figure 3. 4 QQ and Manhattan Plots of SardiNIA G6PD Trait Association from Exome 
Chip Single Variant Test 
 
 
Autosomal and X-chromosomal empirical kinship matrices were estimated from 
common variants with frequency >0.05 on Exome Chip, and used for fitting the 
variance component model for this analysis. Autosomal and X-chromosomal 
heritability was estimated to be 28% and 27% individually. Genomic control was 
0.99.  
a) is the QQ plot for all variants.  
b) is the QQ plot for variants with frequency <5%.  
c) is the Manhattan plot of all variants. Green dots are variants that passed p-
value threshold using Bonferroni correction, which was 6.13x10-7. 
 
  
a) b) 
c) 
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Supplementary 
 
Figure S3. 1 Pedigree Structure Used in Simulation 
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Figure S3. 2 QQ Plots under Null with no Autosomal Contribution to Variance 
 
 
 
Quantitative traits were simulated in 5,000 individuals with pedigree10 (see Figure 
S3.1 for structure) under the null model. Autosomal heritability was 0% and X 
heritability was 10%. 2,000 genes were simulated starting from founder haplotypes 
and then gene-drop to children along pedigrees. Variant with frequency <0.01 were 
grouped for four gene-level tests and then QQ plots were generated based on the 
obtained p-values.  
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Figure S3. 3 QQ plot when Ignoring X Variance Component 
 
 
 
The QQ plot was generated from associations of 2,000 genes under the null where 
autosomal and X heritability was 40% and 10%, individually. A simple variance 
component model was fit where X variance component was ignored.   
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Figure S3. 4 Power Comparison in All-male vs. All-female Samples to Detect a Gene 
Explaining Various Proportion of Trait Variance in Females 
 
 
Power was averaged over 1,000 simulations. 10,000 haplotypes for a gene with 1k 
base-pair were simulated. Then 20% variant with frequency <0.01 were assigned to 
be causal. Effect sizes of causal variants were calculated such that causal variants 
altogether explain various trait variance in females, ranging from 0.5% to 2%. Then 
quantitative traits of 5,000 unrelated individuals were simulated based on causal 
effects and were either all male or all female. Simple burden test was performed on 
each simulated data set.  
  
   
 87  
Figure S3. 5 Power to Detect an Autosomal Gene and an X-linked Gene 
 
10,000 haplotypes with1k base-pairs in length were simulated. 20% variants with 
frequency <0.01 were selected to be causal and effect sizes calculated such that the 
gene explains 0.5%-2% proportion of trait variance in females. Founder haplotypes 
of 5,000 individuals with pedigree structure shown in Figure S3.1 were randomly 
selected from the pool of haplotypes. Children haplotypes were gene-dropped from 
parents haplotypes. Quantitative traits were simulated with 40% autosomal 
heritability (for autosomal associations) and 10% X heritability plus 0% autosomal 
heritability (for X-linked associations) together with causal gene effects.  
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Table S3. 1 Autosomal and X Chromosomal Heritability Estimates Under the Null with no 
Autosomal Polygenic Effects 
 
Polygenic 
Source 
True 
Heritability 
Mean 
Estimates SE 
Lower 
95% 
Confidence 
Level 
Upper 
95% 
Confidence 
Level 
Chr X 0.05 0.04 0.0007 0.041 0.044 
Autosome 0.00 0.01 0.0008 0.013 0.016 
Chr X 0.15 0.14 0.0007 0.141 0.143 
Autosome 0.00 0.01 0.0007 0.013 0.016 
Chr X 0.10 0.09 0.0007 0.091 0.093 
Autosome 0.00 0.01 0.0007 0.013 0.016 
Chr X 0.25 0.24 0.0007 0.239 0.242 
Autosome 0.00 0.02 0.0008 0.014 0.017 
Chr X 0.20 0.19 0.0007 0.190 0.193 
Autosome 0.00 0.02 0.0008 0.014 0.017 
Chr X 0.35 0.34 0.0008 0.339 0.342 
Autosome 0.00 0.02 0.0008 0.014 0.017 
Chr X 0.30 0.29 0.0008 0.289 0.292 
Autosome 0.00 0.02 0.0008 0.014 0.017 
Chr X 0.40 0.39 0.0008 0.388 0.391 
Autosome 0.00 0.02 0.0008 0.015 0.018 
Chr X 0.00 0.00 0.0002 0.003 0.004 
Autosome 0.00 0.01 0.0004 0.005 0.006 
 
Each grid represents a simulation setting with a certain combination of autosomal 
heritability (h2) and X chromosomal heritability (hx2). Results were summarized 
from 1,000 simulations.  
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CHAPTER 4: IDENTIFYING TRAIT-ASSOCIATED RARE VARIANTS 
BEFORE SEQUENCING  
Introduction 
Most non-synonymous, splice altering, and protein truncating variants are very 
rare[Abecasis et al. 2010; Abecasis et al. 2012; Marth et al. 2011; Nelson et al. 
2012].Because these variants have clear functional consequence, discovery of association 
between a medically relevant trait and these variants can provide clear insights about 
disease biology.[Boucas et al. 2013; Raychaudhuri et al. 2011; Zhan et al. 2013] Next-
generation sequencing has been accelerating the discovery of these rare trait-associated 
variants, but remains expensive.  
 
Prioritizing individuals and families to sequence from existing samples remains 
important, and often relies on the simple identification of phenotypic extremes.[Ahituv et 
al. 2007; Cohen et al. 2004; Cohen et al. 2006; Sanna et al. 2011] This approach can 
enrich samples for rare alleles with large effects, and facilitates discovery of trait-
associated rare variants.[Guey et al. 2011; Kryukov et al. 2009; Sanna et al. 2011; Van 
Gestel et al. 2000] Another popular strategy is to study family samples, because 
pedigrees make it simpler to identify multiple copies of trait associated rare variants. 
Many publications successfully discussed selection strategies typically for sibship 
samples to gain association power.[Abecasis et al. 2001b; Kwan et al. 2009; Risch and 
Zhang 1995; Risch and Zhang 1996] In addition, in families, it may often be possible to 
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sequence a subset of individuals and, through genotype imputation, propagate this 
information to their relatives.[Cheung et al. 2014] This strategy is implemented in tools 
such as PRIMUS,[Staples et al. 2013] which selects a set of maximally unrelated 
samples; GIGI-Pick,[Cheung et al. 2014] which optimizes genotype imputation in 
candidate regions based on pedigree structure and genotype; and ExomePicks,[Abecasis 
2011] which selects individuals from large families to maximize ability to estimate and 
impute rare variant haplotypes.  
 
Here, we propose a new approach for prioritizing individuals for sequencing. RAREFY 
selects individuals and families that are likely to carry trait-associated rare variants. The 
approach models background polygenic effects using a variance component model and 
can adjust for covariates and the effects of known variants. Our approach relies on the 
intuition that by examining the segregation of phenotypes across the entire pedigree, it 
should be possible to better prioritize individuals for sequencing than by examining 
individual phenotypes alone. For example, intuitively, we might expect that an individual 
with an extreme phenotype who has a parent and a child who are also phenotypically 
extreme in the same direction may be more likely to carry a variant of large effect than an 
individual whose parent and child are phenotypically average (Figure S4.1). Our 
approach considers all possible variant segregation patterns and prioritizes individuals 
and families that seem more likely to carry a trait associated rare variant.  
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We show that for a fixed sequencing effort our approach has more power to discover and 
associate more trait-associated rare variants than methods that focus on individuals 
phenotypic extremes alone.  
 
Method 
In this section, we first explain the variance component model that is used to handle 
familial relationship. Then, we describe our approach for small pedigrees, where we 
enumerate and evaluate all possible genotype configurations, conditional on family 
structure. This is followed by a description of a Markov Chain Monte Carlo (MCMC) 
approach for larger pedigrees to evaluate the most likely genotype configurations, 
conditional on family structure and available phenotypes. The reason that the MCMC 
method is introduced is that for large pedigrees computational cost grows exponentially 
using the former approach, but the MCMC approach avoids the enumerations thus makes 
our method computationally feasible for large pedigrees. Finally, we describe simulations 
and the data set used as a real data example. 
 
Modeling Familial Relatedness 
Our first step is to calculate residuals of quantitative traits, taking account familial 
relationship and key covariates. We assume the usual linear model[Falconer and Mackay 
1996]  
E(𝐲𝐢) = 𝛍 + 𝐗𝐢𝛃𝐱, 
(Equation 1)  
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where 𝐲𝐢 is the phenotype vector for n individuals in the i
th
 family, 𝛍 is the vector of 
population mean, 𝐗𝐢 is the design matrix, and 𝛃𝐱 is the vector of covariate effects. Then 
𝐲𝐢 follows multivariate normal distribution with mean 𝛍 + 𝐗𝐢𝛃𝐱 and covariance matrix 
𝛀𝐢 = σg
2𝐊𝐢 + σe
2𝐈, where 𝐊𝐢 is the kinship matrix,[Lange 1997] σg
2 is the genetic variance 
component, and σe
2 is residual environmental variance. Parameters 𝛍, 𝛃𝐱, σg
2, and σe
2 are 
estimated using maximum likelihood. For convenience, we define 𝛀?̂̂? = σg2̂𝐊𝐢 + σe2̂𝐈, as 
the estimated covariance matrix of 𝐲𝐢 and the trait residuals vector as 𝐲?̃? = 𝐲𝐢 − ?̂? − 𝐗𝐢𝛃?̂?. 
Method for Smaller Pedigrees 
Our approach calculates the expected number of copies of a rare allele in each individual 
or family for a putative rare variant with large effect size, based on observed phenotype 
and estimated variance components and fixed effects. Let 𝐠𝐢 = (gi1, gi2, … , gin), be a 
vector of genotypes coded 0, 1, or 2 copies of the rare allele. Define a random variable Sij 
as the count of trait-associated rare alleles in the j
th
 individual of the i
th
 family. Then the 
expectation of Sij given the residual vector 𝐲?̃? is 
E(Sij|𝐲?̃?) = ∑ gijP(𝐠𝐢|𝐲?̃?) =
∑ gijP(𝐲?̃?|𝐠𝐢)P(𝐠𝐢)𝐠𝐢
∑ P(𝐲?̃?|𝐠𝐢)P(𝐠𝐢)𝐠𝐢𝐠𝐢
 
(Equation 2) 
where the summations range over all possible genotype configurations. P(𝐠𝐢)  is the 
probability of observing the genotype configuration 𝐠𝐢  in a pedigree. P(𝐲?̃?|𝐠𝐢)  is the 
conditional probability of residuals given a specific genotype configuration 𝐠𝐢.  
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To calculate P(𝐲?̃?|𝐠𝐢) in equation (2), we let βg be the postulated additive effect size of a 
trait-associated variant with frequency p. Then 𝐲?̃?|𝐠𝐢  follows the multivariate normal 
distribution with mean βg𝐠𝐢  and covariance 𝛀?̃? = σg2̃𝐊𝐢 + σe2̂𝐈 , in which σg2̃ = σg2̂ −
2p(1 − p)βg
2. We write the conditional likelihood as 
 
P(𝐲?̃?|𝐠𝐢) = (2π)
−
n
2|𝛀?̃?|
−
n
2exp {−
1
2
(𝐲?̃? − βg𝐠𝐢)
T
𝛀?̃?
−𝟏
(𝐲?̃? − βg𝐠𝐢)} 
(Equation 3) 
 
It is straightforward that the expected count of the rare alleles for the i
th
 family can be 
calculated using 
 
E(Si|𝐲?̃?) = ∑ E(Sij|𝐲?̃?)𝒋 . 
(Equation 4) 
 
For convenience, we name E(Si|𝐲?̃?) as the RAREFY-Family score and E(Sij|𝐲?̃?) as the 
RAREFY-Individual score. 
 
As described, our method requires enumerating all possible genotype configurations in a 
pedigree and calculating the likelihood for each. The complexity of this calculation is 
exponential with family size n. In our implementation, exhaustive enumeration is only 
feasible for pedigrees with <25 individuals. In the next section, we describe a MCMC 
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approach for larger pedigrees. In our example dataset, we apply the MCMC approach to 
pedigrees including as many as 1,453 members. 
MCMC for Larger Pedigrees 
For large pedigrees, we use a Metropolis-Hastings[Hastings 1970; Metropolis et al. 1953] 
algorithm to sample from the posterior distribution of P(𝐠𝐢|𝐲?̃?). For a family with n 
individuals, we consider each of 3
n
 possible genotype vectors as a potential state for a 
Markov chain. The Markov chain starts by randomly assigning founder genotypes and 
then randomly propagating founder alleles to offspring according to Mendel’s laws. After 
the initial likelihood is calculated, new states are proposed by randomly selecting an 
individual to update in the genotype vector. The probability of a state at the  iteration is  
 
L(t) = P(𝐠𝐢
(𝐭)|𝐲?̃?) ∝ P(𝐲?̃?|𝐠𝐢
(𝐭))P(𝐠𝐢
(𝐭)), 
 
where P(𝐲?̃?|𝐠𝐢
(𝐭)) is calculated from Equation 3. If the updated genotype vector is 
inconsistent with Mendelian inheritance, then  P(𝐲?̃?|𝐠𝐢
(𝐭)) is zero. 
 
After convergence (typically millions of iterations), allowing burn-in period and thinning, 
we estimate the posterior mean of the genotype vector  𝐠𝐢|𝐲?̃?  of the i
th
 family. Then 
RAREFY-Individual score E(Sij|𝐲?̃?) can be obtained from the posterior mean of 𝐠𝐢|𝐲?̃?. 
RAREFY-Family score E(Si|𝐲?̃?) can then be calculated using Equation 4. 
 t
th
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Simulations 
We considered three types of pedigree structures (See Figure S4.2) in simulations: a 
nuclear family with three siblings and extended 3-generation pedigrees with 10 and 15 
individuals, respectively. To simulate genotypes, we first simulated haplotypes for 
founders, using a population genetic model implemented in ms[Hudson 2002] to simulate 
1,000 base-pair sequences, and then used gene-dropping to propagate these to other 
individuals in the pedigree. Causal single variants were simulated with effect size 1 or 2 
trait standard deviations, and causal genes were simulated to explain 0.1-1.0% trait 
variance. In causal genes 20% variants with frequency <1% were selected to be causal 
and each assigned the same amount of trait variance (resulting in a different effect size 
for each variant). Total heritability for simulated quantitative traits was 40%, including 
polygenic background effects. 
 
Empirical Significance Level and Power  
We evaluated association power empirically using a family-based score test.[Chen and 
Abecasis 2007; Feng et al. 2014] 1,000 simulations were used to obtain power of each 
setting. To mimic the process of real studies, we first used phenotypes from the entire 
sample to estimate variance component and fixed effect parameters and to select 
individuals for “sequencing”. In the association analysis stage, only genotypes of these 
selected individuals contributed to association tests. Because normality is usually violated 
and sample sizes were often small after selection, we estimated association p-values 
empirically using 300,000 permutations. In each permutation, we first simulated founder 
haplotypes for the variant using estimated founder allele frequency in selected samples, 
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and then used gene-dropping to simulate offspring haplotypes. The Besag-Clifford 
stopping rule[J. and P. 1991] was used to approximate the p-value with  faster 
computation. Power was calculated as the proportion of the original 1,000 datasets that 
showed evidence of association at empirical significance level of 10
-5
, due to limitation of 
computational cost from massive amount of permutation tests. This could limit our 
insight of the performance of our method at lower significance levels..  
Selection Methods for Comparison  
To evaluate the strengths and weaknesses of our approach, we compared RAREFY-
Individual and RAREFY-Family methods with two other popular approaches: Extreme 
Phenotype and Extreme Unrelated Phenotype strategies. All methods used residuals 
generated after adjusting for study-specific covariates and known variants in linear 
models. The Extreme Phenotype method selects individuals with extremely high or low 
residuals. The Extreme Unrelated Phenotype method picks unrelated individuals with 
extremely low or high residuals, based on a modified implementation of the PRIMUS 
approach for selecting a maximum set of unrelated individuals with extreme phenotypes. 
We compared both discovery power (the number of the trait associated allele among 
selected individuals) and association power.  
Exemplar Dataset  
To evaluate the performance of our approach we also reanalyzed LDL-cholesterol levels 
in sample of individuals from the Lanusei valley in Sardinia (see Table S4.2 for 
descriptive statistics), adjusting for age, sex, and squared age as covariates. Quantitative 
traits were quantile normalized before analysis but covariates were not transformed. The 
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SardiNIA sample includes 6,602 genotyped individuals (9,720 individuals including non-
genotyped founders and ancestors). The largest pedigree includes 1,453 individuals 
spanning five generations. Genotypes were called using the Illumina GenCall algorithm 
in combination with zCall V2.2. Detailed QC procedures can be found in Pistis et 
al.[Giorgio et al. 2014] 
Results 
In this section, we compare the power to detect trait-associated rare variants and genes 
using RAREFY and alternative approaches. We also explore the impact of misspecified 
parameters on RAREFY analyses. Finally, we apply RAREFY to a study of LDL 
cholesterol in the isolated population of SardiNIA. 
Discovery Power  
To evaluate power for a single trait-associated rare variant, we simulated family samples 
of various sizes (N=2,500~20,000) and configurations (see Figure S4.2) and a causal 
variant with minor allele frequency 0.001 with effect size 1 or 2 trait standard deviations. 
We then compared the number of causal alleles captured using the RAREFY, Extreme 
Phenotype, Extreme Unrelated Phenotype, and random selection strategies.  
 
Figure 4.1 shows that the RAREFY-Individual and RAREFY-Family methods always 
provide largest discover power for trait-associated rare alleles. Random selection 
provided the least power for variant discovery. Selecting extreme individuals without 
regard to their relatedness (the Extreme Phenotype approach) was better than selecting 
unrelated individuals with extreme phenotypes (the Extreme Unrelated Phenotype 
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approach) but still performed less well than RAREFY. For example, for a variant with 
frequency 0.001 and effect size 1 trait standard deviation, sequencing 200 individuals 
from the original sample of 20,0000 individuals using RAREFY captured approximately 
the same number of causal alleles (~4 copies) as sequencing 2,000 individuals selected 
randomly. Similarly, sequencing 500 individuals by RAREFY was as efficient as 
sequencing 1,000 or 1,800 individuals selected by Extreme Phenotype or Extreme 
Unrelated Phenotype strategies. When effect sizes are larger (2 trait standard deviations), 
RAREFY performed even better (see Figure 4.1B). For example, sequencing 500 
individuals selected by RAREFY had the same discovery power for causal alleles (~25 
captured) as sequencing 1,800 individuals by Extreme Phenotype method, and as 
sequencing > 2,000 individuals by other strategies.  
 
Figure 4.1 also shows substantial enrichment of rare causal alleles in selected samples 
using RAREFY. For example, in Figure 4.1B, applying RAREFY-Individual to a sample 
of 20,000 individuals (and on average of 40 trait associated variants), prioritizing 1,000 
individuals captured 28.2 causal alleles (versus 20.8 selecting phenotypic extremes alone) 
with effect size 2 trait standard deviations. In other words, sequencing 5% individuals 
captured 70.5% rare alleles, increasing the frequency of trait-associated variants from 
0.1% in the original sample to 1.4% in the selected sample, a 14-fold increase. 
 
Figure 4.2 shows that, with a fixed number of individuals to sequence, selecting from 
larger samples improves the value of selected individuals. For example, for a causal 
variant with frequency 0.001 and an original sample with 2,500 individuals, sequencing 
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1,000 captured 4.6 causal alleles (almost all of the 5 copies in the original sample). When 
the sample of phenotyped individuals increased to 20,000, the same sequencing effort 
(1,000 individuals sequenced) captured 28.2 causal alleles. Thus enriched allele 
frequency in two selected samples of 1,000 individuals was 0.2% and 1.4%, respectively. 
 
Complex diseases are likely to be affected by multiple variants.[Willer et al. 2008] To 
explore this situation, we simulated a 1,000 base pair sequence where 20% of variants 
with frequency <0.01 were trait-increasing and, altogether, explained 1% of trait 
variance. In this setting, each variant has a different effect size and the model used by 
RAREFY to analyze the data is misspecified. Again, both RAREFY-Family and 
RAREFY-Individual scores were able to prioritize more causal alleles for “sequencing” 
(Figure S4.3), and the RAREFY-Individual method was able to pick the most causal 
alleles. Since variants with opposite effects can reside in the same gene,[Abifadel et al. 
2003] we simulated genes where half of causal variants were trait-increasing and the 
remainder were trait-decreasing. Figure S4.4 shows that, among the methods examined, 
RAREFY provided the best power compare to others in this situation.  
  
RAREFY methods performed well regardless of pedigree size. Figure S4.3-S5 show that 
pedigree structure and size does not affect discovery power of RAREFY-Individual 
method. In Figure S4.3-S5, Discovery power for RAREFY-Family method decreased 
with increasing family size, but remained second best.  
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Impact of Model Misspecification 
Since RAREFY analyses requires postulating a frequency and effect size for trait-
associated variants, we evaluated the impact of misspecifying these parameters. Figure 
S4.6 shows that choice of MAF has almost no effect on discovery power of RAREFY 
when a true MAF ranged from 5x10
-4
 and 0.01 is misspecified between 5x10
-4
 and 0.05, 
and effect size is specified correctly. Figure S4.7 shows that RAREFY continues to 
outperform selection strategies based on individual phenotypic extremes when true effect 
size ranged from 0.5 and 1.5 was misspecified as between 0.25 and 2.5, and MAF was 
specified correctly. However, parameter settings closer to the true (and typically 
unknown) effect size produced better discovery power. With the expectation that most 
interesting trait-associated variants for complex traits will have  effect sizes greater than 
0.5 standard deviations, together with simulation results shown in Figure S4.6, we 
choose MAF 0.001 and effect size 1 as default parameter values in RAREFY. All 
simulation results shown in previous sections were based on this default parameter 
setting. 
Association Power 
To evaluate power of association analysis in samples prioritized by RAREFY, we 
performed single variant association score test[Chen and Abecasis 2007] on selected 
samples evaluating p-value empirically using 300,000 gene-drops per simulated sample. 
Figure 4.3 and Figure 4.4 shows that, among the methods we considered, RAREFY-
Family and RAREFY-Individual provides the largest and second-largest power for 
detecting a single trait-associated variant and random selection provides the least power. 
For example, using significance level 10
-5
, Figure 4.3 shows that sequencing 400 
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individuals or more from a sample of 20,000 individuals provides 89.9% and 82.8% 
power by RAREFY-Family and RAREFY-Individual; however, to obtain power >80%, 
Extreme Phenotype based selection required sequencing 800 individuals or more. 
Sequencing 2,000 individuals selected randomly only provided 22% power. Figure 4.4 
shows that, with fixed sequencing effort, selecting from a larger sample provides larger 
association power. For example, by RAREFY-Family, selecting 1,000 from 5,000, 
10,000, and 15,000 individuals to sequence provides 48.1%, 78.9%, and 91.7% power 
respectively. Obtaining 80% power by selecting 1,000 individuals with Extreme 
Phenotypes required >18,000 phenotyped individuals. 
 
Analysis of Exemplar Data Set  
To evaluate RAREFY in real data, we analyzed LDL cholesterol levels in 6,602 
individuals from the Lanusei valley in Sardinia. This is a relatively isolated population 
and includes many families, small and large[Pilia et al. 2006].  Age, sex and square of 
age were used as clinical covariates (see Table S4.1 for descriptive statistics). Known 
associated variants (See Table S4.2 for list of variants) were also used as covariates to 
obtain better discover power by RAREFY. We then evaluated our ability to identify 
carriers of rare variant V578A[Sanna et al. 2011] in LDLR, which  is unique in SardiNIA 
and has frequency 0.005 (61 copies in the sample) and effect size 23.7mg/dl (0.63 
standard deviation).  To show the impact of misspecification of parameters to RAREFY 
power, we used various parameter combinations to run RAREFY. Figure 4.5 shows that 
RAREFY typically provided higher power than methods based on selecting phenotypic 
extremes, even after parameter misspecification. For example, sequencing 1,000 
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individual by RAREFY using the default parameter settings (MAF=0.001, effect=1), 
RAREFY captured 26 copies of the rare allele, but sequencing Extreme Phenotype 
individuals captured 19. Sequencing 2,000 individuals (<1/3 of the entire sample), 
captured more than half of the rare alleles (32 copies). Figure 4.5 also shows that 
RAREFY prioritizes carriers even when only small number of individuals are sequenced. 
For example, the top 100 individuals prioritized by RAREFY include 11 copies of V578, 
but those selected based on phenotype extremes alone include only 3. Figure S4.9 and 
S10 show that including known variants as covariates boost RAREFY power but provide 
only a limited benefit when selecting phenotypic extremes.       
Tool and Computational Performance 
We implemented our method in a C++. RAREFY is a command line tool that uses 
Merlin[Abecasis et al. 2002] format input files and can prioritize carriers of trait-
increasing and trait-decreasing rare variants in small or large pedigrees. RAREFY rapidly 
handles most small pedigrees and supports parallel computing for samples including 
larger pedigrees. A RAREFY analysis of a sample of 20,000 individuals in 4,000 nuclear 
families of size five, searching for both trait-increasing and trait-decreasing variants, 
required 10.95 seconds on a single CPU. A RAREFY analysis of a family with ~1,500 
individuals using MCMC with 50,000,000 iterations in five chains takes 8 hours using 5 
CPUs.  
Discussion 
We describe a new approach to prioritize individuals and families that carry trait-
associated rare alleles. Using simulation and real data analysis, our approach greatly 
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outperforms selection based on extreme phenotypes alone. RAREFY is able to handle 
both families and unrelated samples.  
 
Our RAREFY-Individual method is able to capture more associated rare alleles than 
RAREFY-Family method, but our RAREFY-Family approach provided greater power for 
association analyses in our simulations. Part of the explanation, is that the RAREFY-
Family method typically results in samples that include more diverse sets of phenotypes – 
including family members who are unlikely to carry trait associated rare variants but 
which help estimate phenotypic values for non-carriers.  
 
Adjusting for previously associated variants is helpful in guiding searches for new trait-
associated rare variants. Working in combination, these variants can account for extreme 
phenotypes in many individuals. We suggest genotyping samples at known loci and using 
these genotypes to adjust phenotype residuals. When direct genotyping is not feasible, 
existing array data together with genotype imputation procedure can also be 
useful.[Cheung et al. 2014] We do caution that adjusting for previously associated 
common variants could reduce the chance identifying rare causal variants that are in 
linkage disequilibrium with these.  
 
RAREFY could be improved further by specifying a distribution for effect size, instead 
of a fixed value. Normal distribution has been widely used for distribution of effect sizes, 
but an appropriate prior distribution of parameters to specify the variance of the 
distribution of effect sizes should be carefully evaluated. For random effect size, 
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computational cost could also increase exponentially, depends on the distribution 
specified. Another improvement could be optimizing association test statistics, instead of 
discovery power.  
We suggest selecting individuals and families for both trait-increasing and trait-
decreasing rare variants, because both gain-of-function and loss-of-function rare variants 
are typically of interest[Abifadel et al. 2003]. After individuals and families are 
prioritized and sequenced and candidate rare variant are identified, genotyping the entire 
sample for these variants may help confirm and extend potential discoveries. 
 
In summary, RAREFY provides powerful solutions, fast computation, and command-line 
tool to prioritize families and unrelated individuals to sequence among phenotyped 
individuals.  
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Figures  
Figure 4. 1 Number of Alleles Captured for a Rare Variant (MAF=0.001) Sequencing 100-2,000 Individuals from a Sample of 20,000 
Individuals 
 
A single variant with frequency 0.001 with effect size = 1 or 2 trait standard deviation was simulated in founders and gene-dropped to 
children in original samples of 20,000 individuals, with Pedigree5 (see Figure S4.1) family structure.  
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Figure 4. 2 Number of Alleles Captured for a Rare Variant (MAF=0.001) Sequencing 1,000 Individuals from Original Samples of Various 
Sizes 
 
A single variant with frequency 0.001 with effect size = 1 or 2 trait standard deviation was simulated in founders and gene-dropped to 
children in original samples of various sizes (2,500~20,000), with Pedigree5 (see Figure S4.1) family structure.  
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Figure 4. 3 Association Power of Sequencing 200-2,000 Individuals from 20,000 Individuals 
 
 
200-2,000 Individuals were selected from 20,000 individuals, using various selection strategies. 300,000 
permutations and significance level 10
-5
 were used to obtain association power. All phenotyped samples 
were used to fit variance component model. Un-selected samples were set to have genotypes missing. 
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Figure 4. 4 Association Power of Sequencing 1,000 Individuals from Samples of Various 
Sizes by Different Strategies 
 
1,000 Individuals were selected from original samples with 2,500-20,000 individuals, using various 
selection strategies. 300,000 permutations and significance level 10
-5
 were used to obtain association 
power. All phenotyped samples were used to fit variance component model. Un-selected samples were 
set to have genotypes missing. 
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Figure 4. 5 Power to Discover Rare Allele of V578* from SardiNIA Sample Using 
RAREFY-Individual and Extreme Phenotype Strategies 
 
50-2,000 individuals were selected for sequencing from SardiNIA sample of 6410 phenotyped 
individuals and covariates adjusted. Adjusted LDL values (40 individuals taking cholesterol-
lowering drugs were added 40 to their LDL values) were used as phenotype. LDL values were 
inverse-normalized before fitting linear mixed model. Covariates were age, sex, and squared age, 
together with known variants (See Table S4.2 for list of known variants adjusted).  
*V578A is a rare variant on chr19, position 11227562 in LDLR with minor allele frequency 
0.005 and effect size 0.63 standard deviation, which is unique in SardiNIA sample. It has total 
allele count 61 in the sample.  
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Supplementary 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S4. 1 An Example of Who Are Selected by RAREFY and Phenotypic Extremes 
Alone. 
 
The example family was selected from a simulated sample with 20,000 individuals in 
2,000 families. A trait-associated rare variant with frequency 0.001 and effect 2 standard 
deviation was simulated in founders and then gene-dropped to children. Blue numbers 
represent rank of calculated RAREFY score. Black numbers represent rank of phenotype. 
Individuals marked as red in the pedigrees are carries.  
  
  
 
 
           Carrier 
Rank by RAREFY 
Rank by Phenotype 
4 
1124 
1191 
17969 
3 
347 
6 
130 
1666 
11032 
12249 
13819 
5 
36 
7 
227 
139 
14153 
9 
1440 
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Figure S4. 2 Pedigree Structures Used in Simulations. 
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Figure S4. 3 Gene-level Discovery Power Selecting from 20,000 individuals and All Causal Variants were Trait-Increasing 
DNA sequences of 1,000 base-pair were simulated in founders and then gene drop to children in various pedigree structures 
Pedigree5, Pedigree10, and Pedigree15 (See Figure S4.1). 20% of variants with frequency < 0.01 were selected as causal 
variants and explained 1% trait variance in total. All causal variants were trait-increasing. 200-2,000 individuals were selected 
from samples with 20,000 individuals.  
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Figure S4. 4 Gene-level Discovery Power Selecting from 20,000 individuals and 50% Causal Variants were Trait-Increasing 
DNA sequences of 1,000 base-pair were simulated in founders and then gene drop to children in various pedigree structures Pedigree5, 
Pedigree10, and Pedigree15 (See Figure S4.1). 20% of variants with frequency < 0.01 were selected as causal variants and explained 1% trait 
variance in total. All causal variants were trait-increasing. 200-2,000 individuals were selected from samples with 20,000 individuals.  
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Figure S4. 5 Pedigree Structure and Size on Single Variant Discovery Power. 
A single variant with frequency 0.001 and effect size 2 was simulated in founders and then gene-dropped to children in Pedigree5, 
Pedigree10, and Pedigree15. 200-2,000 individuals were selected from a sample with 20,000 individuals. 
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Figure S4. 6 Effect of Misspecifying MAF on Selection Efficiency 
1000 family samples of 10,000 individuals with Pedigree5 (See Figure1) structure were 
used to collect each data point. True effect sizes were used in these simulations.  
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Figure S4. 7 Effect of Misspecifying Effect Sizes on Selection Efficiency 
1000 family samples of 10,000 individuals with Pedigree5 (See Figure1) structure were 
used to collect each data point. True MAFs were used in these simulations.
   
 117  
 
 
Figure S4. 8 Power to Discover Rare Allele of V578 from SardiNIA Sample Using 
RAREFY-Individual and Extreme Phenotype Strategies. 
 
50-6,400 individuals were selected for sequencing from SardiNIA sample of 6410 phenotyped 
individuals and covariates adjusted. Adjusted LDL values (40 individuals taking cholesterol-lowering 
drugs were added 40 to their LDL values) were used as phenotype. Covariates were age, sex, and 
squared age, together with known variants (See Table S4.1 for list of known variants adjusted).  
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Figure S4. 9 Effect of Adjusting Known Variants to RAREFY and Extreme Phenotype Methods. 
50-2,000 individuals were selected for sequencing from SardiNIA sample of 6410 phenotyped individuals and covariates adjusted. Adjusted LDL values 
(40 individuals taking cholesterol-lowering drugs were added 40 to their LDL values) were used as phenotype. Covariates were age, sex, and squared age, 
together with known variants (See Table S4.1 for list of known variants adjusted).  Default parameters (MAF=0.001 and effect size =1) were used 
running RAREFY. 
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Table S4. 1 Summary Statistics for LDL in SardiNIA Sample. 
 
  
Sample 
Size* 
Male Female 
N Mean Median Min Max 
Age 
(mean, 
median) N Mean Median Min Max 
Age (mean, 
median) 
SardiNIA 6290 2670 129.5 128.2 27.4 330.5 44.1, 42.4 3620 125.9 132.4 27.9 293.3 43.7, 42.0 
 
* Counting samples who were phenotyped and had age and sex recorded, and known variants genotyped (See Table S4.2 
for list of known variants adjusted).   
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Table S4. 2 Variants Known to be Associated to LDL and Adjusted in Analysis. 
 
Chr:Pos Status* Chr:Pos Status Chr:Pos Status Chr:Pos Status 
1:25775733 included 2:27741237 included 6:161010118 included 12:121388962 included 
1:55496039 included 2:44065090 included 7:21607352 included 12:121416650 included 
1:55504650 included 2:44072576 included 7:44579180 included 14:24883887 included 
1:55505647 included 2:44073881 included 8:9183358 included 16:56993324 included 
1:63025942 included 4:89039082 included 8:9185146 included 16:72108093 included 
1:63118196 included 5:74625487 included 8:59388565 included 17:45425115 included 
1:109817590 included 5:74648603 included 8:126482077 included 19:11195030 not included  
1:109817838 included 5:74651084 included 8:126490972 included 19:11202306 not included  
1:109818306 included 5:74655726 included 8:126504726 included 19:11210912 not included  
1:109818530 included 5:74656539 included 8:145043543 included 19:11238473 not included  
1:109822166 included 5:156390297 included 9:91540059 included 19:19407718 not included  
1:207875175 included 5:156398169 included 9:136155000 included 19:19407718 not included  
1:220973563 included 6:16127407 included 10:113933886 included 19:19658472 not included  
1:234858597 included 6:16161425 included 11:61569830 included 19:19789528 not included  
2:20903015 included 6:16197194 included 11:61597212 included 19:22614122 not included  
2:21231524 included 6:26093141 included 11:116603724 included 19:45395266 not included  
2:21232195 included 6:32412435 included 11:116607437 included 19:45412079 not included  
2:21232195 included 6:33143948 included 11:116648917 included 19:45422946 not included  
2:21263900 included 6:116312893 included 11:116652423 included 20:39091487 included  
2:21286057 included 6:131256364 included 11:126243952 included 20:39228784 included  
2:21288321 included 6:160578860 included 12:112072424 included 20:39672618 included  
 
*: Variants from chr19 were not included in analysis, in case of possible LD with LDLR V578 variant that we are interested in testing.  
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CHAPTER 5: SUMMARY AND FUTURE DIRECTIONS 
 
Summary  
In this dissertation, I discuss efficient study design for sequencing-based GWAS, 
describe a novel approach to prioritize informative families and individuals to sequence 
first, and proposed gene-level association methods for both single studies and meta-
analyzing family and population samples across multiple studies for both autosomal and 
X-linked genes.  
 
In chapter 2, I demonstrate that with the same sample size, family samples have larger 
power to detect trait-associated rare and low-frequency variants with moderate to large 
effect sizes because family samples can allow multiple copies of trait-associated rare 
alleles to be observed in a single family or a “Jackpot” effect. Although on average, when 
sample size is the same, rare allele count is expected to be the same in family samples 
and population samples, variability in allele counts is larger in families particularly in 
pedigrees with many descendants per founder. This power advantage is particularly 
obvious for variants with extremely low frequency, for example singletons and 
doubletons where population samples barely have any power, or low-frequency with 
large effect sizes. When variants become more frequent or effect sizes become moderate 
to low, population samples quickly catch up and exceed family samples in power.  
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In chapter2, I also describe a series of computationally efficient gene-level tests for 
family samples including burden, variable threshold, and sequence kernel association 
tests that are built upon single-variant summary statistics and covariance matrices without 
utilizing raw data. This also makes our methods to be easily adapted to gene-level tests in 
meta-analysis where raw data sharing is usually not feasible across studies. The fact that 
all gene-level statistics are reconstructed from single-variant scan makes it 
computationally efficient to perform multiple gene-level tests and using various grouping 
strategies without going through raw data repeatedly. Together with our efficient 
implementation in C++ code and computational considerations whenever possible in 
terms of speed and memory use, our software uses the least CPU time and memory 
compare to other implementations. Another major difference between our methods and 
others is that our variance component model is flexible enough to handle known familial 
relatedness, cryptic relatedness and population structure. Using simulations, I confirm 
that burden type tests are more powerful than kernel-based tests when number of causal 
variants in a gene is large and all causal variants have the same direction in effect sizes, 
and kernel-based tests are more powerful when number of causal variants in a gene is 
small or causal variants have opposite directions in effect sizes. I further demonstrate the 
usage of our method and software by meta-analyzing SardiNIA and HUNT exome chip 
data for HDL level by not only successfully detect known genes that are associated with 
HDL but also particularly detect APOC3 with a smaller burden p-value using ~12,000 
individuals than previous studies where 10 times more samples were analyzed [Crosby et 
al. 2014].  
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In chapter 3, I describe a series of gene-level tests for X-linked variants and genes in 
families and unrelated individuals. I describe the variance component model where 
autosome and chromosome X polygenic contributions are modeled separately. This 
variance component is flexible enough to model familial relatedness, cryptic relatedness, 
and population structure manifested through both autosome and chromosome X. I further 
describe the method to estimate relatedness from genotypes of X-linked markers to model 
phenotypic correlation contributed by X chromosome. Our work assumes complete X-
inactivation in female, and code genotypes of females as 0,1, or 2 and males as 0 or 2 
correspondingly. In this case, male samples contribute twice the variance of female 
samples toward total trait variance for genes of the same effect sizes. Using simulations, I 
show that our gene-level association methods and implementation are well controlled 
under the null. I also demonstrate that there is larger power to detect an X-linked gene 
than an autosomal gene of the same effect sizes, and more males in a sample provides 
larger power to detect an X-linked gene when sample size is fixed. Finally, I demonstrate 
the usage of our methods and tool using SardiNIA quantitative traits and report the 
association of G6PD with multiple traits measured in this study.  
 
In chapter 4, I describe a novel likelihood-based approach to prioritize individuals who 
are likely to be carriers of traits associated rare variants, when budget is limited but 
sequencing cost is high. I describe the exact calculation for small pedigrees and an 
MCMC approach to estimate the quantity when exact calculation is not feasible to large 
pedigrees. By simulations, I demonstrate that our method has larger power in both 
capturing trait-associated rare alleles and detecting association of these variants compare 
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to selecting individuals with phenotypic extremes alone. I also demonstrate that the 
constant prior value of frequency and effect sizes have minimal effect on power if they 
are specified within a reasonable range. Using SardiNIA data where the largest family 
has ~1,200 individuals, I demonstrate the usage and computational cost of our method 
and implementation and show that RAREFY has larger discovery power than others. 
 
Future Directions 
There are many open questions in sequencing-based association studies. They can be 
statistical and computational challenges. In the future, I seek solutions or improvements 
in the following three topics.  
 
First, I seek to develop more efficient statistical method or computational approach to fit 
variance component model in large samples. Our current method and implementation has 
been tested to be able to analyze 20,000 individuals and 200,000 variants in a week on 
*** CPUs. However, larger samples might be available in the near future, which requires 
more efficient implementation and statistical approach. Although a convenient way to 
analyze very large sample is to divide a sample into smaller ones that have the minimal 
relatedness in between, for example, a division by ancestry, the correlation between the 
sub samples is un-avoidable. Also, when multiple variance components are included in 
the model, for example, when chromosome X variance component or shared-environment 
component is included in the model, currently available fast algorithms for simple 
variance component model, which contains only one genetic component and non-shared 
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environment, are not applicable. Faster likelihood maximizing algorithms are in great 
need for this type of variance component models.  
 
Second, there are many interesting topics that need further investigation in meta-analysis. 
In my dissertation, we propose methods to meta-analyze both related and unrelated 
samples or samples with population structure or cryptic relatedness. However, in real data 
analysis, relatedness between samples is possible. This type of relatedness, cryptic or 
distant, is usually ignored. The other topic in meta-analysis that might be interesting is 
that when meta-analyzing genotyping array data across studies, effect size estimates are 
not homogeneous even for the same variant because variants have very different linkage 
disequilibrium patterns in different populations. This issue has more impact on rare 
variants than on common ones because rare variant frequencies are more likely to be 
confounded with population structure and geological locations. Special considerations are 
needed for the existence of heterogeneity in meta-analysis. 
 
Third, there are a few topics that are in need of discussion in chromosome X analysis. 
Our current approach has a few assumptions, for example, variants in male and female 
have the same frequency and effect sizes. These assumptions could easily be violated in 
real data. For example, a gene could be differently expressed between sexes in some 
tissues but not in others, which suggests that male and female might have different 
architecture of regulatory interactions. This could lead to different effect sizes between 
male and female. In this situation, sex and genotype interactions might be a reasonable 
way to evaluate association thoroughly. Also, when frequency for the same variant is 
   
 126  
different between sexes, our basic assumption is violated. Then a different variance 
component model where both female and male variance components are included might 
be more appropriate.  
 
Conclusion 
New problems emerge with rapid improvement in technology in human genetic studies. 
With more biological insight of disease and human health-related traits are revealed, the 
need of appropriate statistical methods and efficient computational solutions will be in 
great need. To this end, I propose power statistical methods and provide computationally 
efficient tools to facilitate the science community with discoveries of rare and low-
frequency variants that contribute to the majority of polymorphism from sequencing 
studies. I evaluate study designs and provide insight on powerful discoveries from 
sequencing-based association studies. I propose powerful approach to identify possible 
carriers of variants of interest to sequence first which could be easily imputed to the rest 
of the sample, to gain power with limited cost. These statistical approach and design 
strategies will facilitate scientific investigators for faster and powerful discoveries.  
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